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Background: Several studies have demonstrated that insulin delivered by 
nasal spray acutely improves cognitive performance in early Alzheimer’s disease.  
Furthermore, the apolipoprotein E-epi\silon-4 allele, a known AD risk factor, appears 
to influence those cognitive responses in a dose dependent manner, with carriers 
exhibiting impaired cognitive performance at higher insulin doses. The neural 
correlates of this phenomenon are however presently undefined.  Hippocampal 
neurons are known to express insulin receptors in high densities, and neuronal 
insulin signaling is thought to modulate long-term potentiation mechanisms, 
suggesting that insulin might act at the hippocampus to generate cognitive 
enhancement.  How the apolipoprotein E-epsilon-4 allele might interact with 
hippocampal insulin responses is not clear however. 
 
Methods: We studied the effects of a single 40IU dose of insulin aspart on 
hippocampal activation in 10 cognitively intact and 18 early AD subjects in a 
double-blind, counterbalanced, crossover memory encoding BOLD-based functional 
MRI study.  We also assessed the effects of insulin on non-cognitive brain function 
with an fMRI motor task, and mean cerebral blood flow with arterial spin-labeled 




hypothesized AD subjects would demonstrate insulin-related increases in 
hippocampal activation, and that insulin-related changes would be greatest in 
apolipoprotein E-epsilon-4 negative AD.  We further hypothesized insulin-related 
increases in mean cerebral blood flow in all subjects.   
 
Results: We observed an apolipoprotein E-epsilon-4 based interaction in 
insulin-related changes in hippocampal activation in AD, with carriers exhibiting 
decreased activation with insulin.  Mean cerebral blood flow did not change 
significantly with insulin administration.   Cognitive performance increased in the 
apolipoprotein E-epsilon-4 negative AD subjects after insulin administration. 
 
Conclusions: There is growing body of research indicating that faulty insulin 
signaling might be a component of AD neuropathology.  The results herein are the 
first description of the neural correlates of insulin-related cognitive enhancement in 
AD, and provide direct evidence that insulin might serve an important 
neuromodulatory role in AD.  Insulin also appears to modulate non-cognitive 
functions in a manner similar to hippocampal activity, suggesting that insulin might 
have wide spread effects on brain physiology, while the arterial spin-labeled MRI 




results furthermore underscore the importance of the apolipoprotein E-epsilon-4 
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There is no cure at the moment for Alzheimer’s disease, and the few 
treatments available do not demonstrate long-term effectiveness.  The prevalence of 
Alzheimer’s disease increases with age, doubling every 5 years over age 65. 
Increased life expectancy in the US and other developed countries has contributed to 
an unprecedented growth in the elderly population and a dramatic increase in AD 
incidence.  There are an estimated 4.5 million people in the US and 20 million 
worldwide with AD (World Health Organization). The cost of AD treatment in the 
US is estimated to be $100 billion annually and is rapidly rising.  Medicare spending 
on Alzheimer's disease is expected to grow to $49.3 billion, a 54% increase over 
2000 costs.  Medicaid spending is expected to grow to $33 billion, an 80% increase 
over costs in 2000. (Kawas & Katzman, 1999) It has been estimated that delaying the 
onset of AD by just 5 years could reduce annual health care costs in the US by $50 
billion, (Kawas & Katzman, 1999) underscoring the importance of developing 
effective strategies for the treatment and prevention of AD.   
 
AD Neuropathology  
 
While the definitive cause of Alzheimer’s disease is presently unclear, most 
research currently focuses on altered amyloid processing and tau phosphorylation as 




of amyloid precursor protein (APP) in both neurons and astrocytes.  Amyloid 
precursor protein degradation may follow either of two pathways.  The more 
common, non-amyloidogenic pathway is characterized by the initial cleavage of APP 
by alpha-secretase, yielding a soluble N-terminal fragment, and a membrane-bound 
C-terminal fragment.  Gamma-secretase next processes the C-terminus fragment into 
a small soluble fragment (P3) as well as an additional membrane-bound fragment.  
(Minati, Edginton, Bruzzone, & Giaccone, 2009) 
 
The amyloidogenic degradation of APP begins with cleavage by beta-
secretase at a site different from that cleaved by alpha-secretase, resulting in a 
smaller soluble N-terminus fragment and a larger membrane-bound C-terminus 
fragment.  Gamma-secretase, the activity of which is modulated by glycogen 
synthase kinase-3 alpha, (GSK-3a) (Phiel, Wilson, Lee, & Klein, 2003) then cleaves 
the C-terminus fragment into a membrane bound polypeptide and an insoluble N-
terminus fragment of either 40 or 42 amino acid residues in length. The plaques seen 
in AD are composed primarily of the 42 amino acid product, known as Abeta-42.   
 
The neurofibrillary tangles associated with AD are composed of 
hyperphosphorylated structural protein tau.  Tau phosphorylation is a normal cellular 




microtubules.  Hyperphosphorylated tau however self aggregates, forming 
neurofibrillary tangles characteristic of AD.  Tau phosphorylation is regulated by at 
least 3 proline-dependent kinases, including GSK-3β, as well as specific 
phosphatases.  (Muyllaert, et al., 2008; Muyllaert, et al., 2006) Dysregulation of tau 
kinase/phosphatase activity is thought to contribute to neurofibrillary tangle 
formation in AD.  The factors that modulate the balance between these kinases and 
phosphatases in AD are not clear. 
  
Insulin and AD Neuropathology 
 
A growing body of research suggests that alterations in insulin signaling 
might contribute to AD pathology.  Key steps in the production of both Abeta42 and 
tau involve GSK-3 activity.  Inhibition of GSK-3a activity modulates gamma 
secretase function, reducing Abeta production. (Phiel, et al., 2003) Similarly, 
inhibition of GSK-3b leads to reduced tau phosphorylation. (Planel, et al., 2007) 
Insulin signaling promotes the phosphorylation and inactivation of GSK-3. (Boron & 
Boulpaep, 2003) Insulin signaling therefore appears to be intimately linked to the 
production of both Abeta and neurofibrillary tangles, and might therefore modulate 
key steps in AD pathogenesis. Insulin furthermore competes with Abeta for 




Kurochkin, 2001; McDermott & Gibson, 1997; Qiu, et al., 1998)  and higher insulin 
levels might therefore inhibit Abeta clearance. 
 
Post-mortem examination of AD brain tissue shows decreased insulin 
receptor density and tyrosine kinase activity in AD relative to age-matched controls, 
(Frolich, Blum-Degen, Riederer, & Hoyer, 1999) suggesting impaired insulin action 
as a component of AD pathology.  Furthermore, decreased insulin, insulin-like 
growth factor, as well as decreased mRNA for insulin receptor substrate (IRS) and 
several insulin signaling intermediates, along with increased GSK-3b activity have 
been described in AD brain. (Steen, et al., 2005) In total, these reports indicate 
altered insulin signaling mechanisms in AD, and have led to the term “type 3 
diabetes” (Steen, et al., 2005) to describe the changes in brain insulin signaling in 
AD. 
 
Streptozotocin (STZ) is used experimentally to inhibit insulin signaling 
mechanisms, and STZ-treated mice exhibit increased tau phosphorylation that is 
partially reversible with insulin administration. (Schechter, Beju, & Miller, 2005)  
Cerebrospinal fluid Abeta42 concentration exhibits a negative correlation with the 
number of neuritic plaques in cortex and hippocampus is AD, (Strozyk, Blennow, 




been shown to be highly predicative of AD development. (Graff-Radford, et al., 
2007) Experimental insulin administration has been shown to increase CSF Abeta42 
in AD, (G. Watson, et al., 2003) and lead to increased plasma Abeta40 concentration, 
(M. A. Reger, et al., 2007) suggesting that insulin might modulate amyloid 
metabolism.  It appears therefore that insulin signaling mechanisms might be 
intimately linked to the expression of the classic neuropathologic hallmarks of AD, 
and that modulation of insulin signaling might modify that expression of AD 
neuropathology and possibly pathologic burden.  
 
Insulin and Brain Structure 
 
  Magnetic resonance imaging is commonly used to assess brain volume as a 
reflection of pathologic burden.  We earlier described a positive correlation between 
whole brain volume obtained from MRI data and peripheral insulin levels during a 3-
hour I.V. glucose tolerance test. (Burns, et al., 2007) These findings suggest that 
chronic insulin levels influence brain structure, and might reflect insulin’s proposed 
influence on AD pathologic burden.  With the knowledge that insulin receptors are 
found in high density in the hippocampus, we narrowed this analysis focusing on the 
relationship between peripheral insulin and hippocampal volume.  The results of this 




between peripheral insulin levels and limbic gray matter volume including the 
hippocampus in AD.  Thus, higher long-term insulin exposure to insulin appears to 
be associated with preserved hippocampal volume in AD.  While speculative, insulin 
might act to inhibit the accumulation of, or promote the clearance of amyloid and/or 
tau in hippocampus in AD.  
It is important to note that insulin degrading enzyme (IDE) metabolizes both 
insulin and Abeta.  (Farris, et al., 2003; Qiu, et al., 1998) While insulin might 
possess neurotrophic or protective properties, chronically elevated insulin levels 
might paradoxically promote Abeta deposition by competitively inhibiting Abeta 
degradation by IDE. PPAR gamma agonists appear to up-regulate IDE transcription, 
(Du, et al., 2009) and have been shown to improve cognitive function in AD as well, 
(Pedersen, et al., 2006; Risner, et al., 2006; G. Watson, et al., 2005) suggesting that 
this class of drug might circumvent the potential negative effects of chronic insulin 
administration on Abeta degradation and offer novel therapeutic opportunities for 
AD patients. 
 









reports of memory enhancement with insulin in AD suggest that insulin may be 
involved in cognitive processes.  Craft et al studies the effects of experimentally 
induced hyperinsulinemia in 23 early AD subjects and 14 cognitively intact older 
adults using a hyperinsuliinemic/euglycemic clamping technique.  Story recall and 
selective attention were improved acutely when insulin levels were elevated, while 
holding glucose levels at baseline in AD.  Memory performance did not however 
improve when glucose levels were raised while holding insulin at baseline levels. (S. 
Craft, et al., 1999)  It appeares therfor that insulin levels can influence cognitve 
performance in AD independent of glucose. 
 
Furthermore the effects of insulin on cognitive performance in early AD 
appear to differ according to apolipoprotein E-epsilon-4 genotype.  Crafet et all 
showed that AD noncarriers specifically exhibit memory facuiitation with insulin 
while carriers do not using the euglycemic clamping method. (S. Craft, et al., 1999)  
This same study showed that glucose disposal also differed according to 
apolipoprotein E-epsilon-4 genotype, wu\ith  AD noncarriers exhibiting less insulin-
mediated glucose disposal than AD carriers or control subjects.  Specifically how 
apolipoprotein E-epsilon-4 genotype influences cognitive enhancement in AD is not 





 More recently, insulin delivered via nasal spray has been shown to improve 
memory similar to IV administration, without the risk of hypoglycemia. Reger et al 
showed that  a single dose of insulin delivered via nasal spray facilitated recall in 13 
early apolipoprotein E-epsilon-4 negative AD subjects , while carriers did not 
respond at a 20IU dose and performed below baseline after a 40IU dose of 
insulin.(M. Reger, et al., 2006)   
 
Plasma glucose and insulin levels do not appear to change significantly after 
intranasal administration of insulin.  (M. Reger, Watson, Green, Baker, et al., 2008; 
M. Reger, Watson, Green, Wilkinson, et al., 2008; M. A. Reger & S. Craft, 2006; M. 
A. Reger, et al., 2006)  These studies collectively demonstrate improved 
performance during memory encoding tasks, commonly word and story recall, when 
tested within about 15 minutes of insulin administration., suggesting that the nasal 
route of administration is a safe and effective method to study the acute effects of 
insulin on cognitive function.  Rat studies have shown that IGF-1, structurally 
similar to insulin, might access the CSF via bulk flow along the outside of the 
trigeminal nerve (Thorne, Pronk, Padmanabhan, & Frey, 2004)  and thereby bypass 





 Insulin apart appears to be superior to regular insulin in provoking memory 
enhancement in AD. (Benedict, et al., 2007) The B28 proline residue in regular 
insulin is replaced with aspartic acid, inhibiting self-aggregation.  Thus, the smaller 
effective molecular size of insulin aspart appears to allow more efficient CSF access 
when delivered via nasal spray.  

































The memory effects of insulin have also been shown to differ according to 
apolipoprotein-E-epsilon-4 genotype in AD.  Cognitive enhancement appears to be 
most evident in AD non-carriers, (Craft, et al., 2003; S Craft, et al., 2000) and at 
higher insulin doses (40IU vs 20IU via nasal spray) carriers may show reduced 
performance. (M. A. Reger, et al., 2006) The apolipoprotein-E-epsilon-4 is a known 




(Saunders, et al., 1993) Those AD patients without an apolipoprotein-E-epsilon-4 
allele are at increased type 2 diabetes risk compared to AD carriers, (Profenno & 
Faraone, 2008) suggesting a relationship to peripheral insulin sensitivity, and 
apolipoprotein-E-epsilon-4 based differences in insulin action although the 
underlying mechanism is unknown. 

























Aim 1: Assess the Effects of Insulin on Explicit/Declarative Memory Processes 
in AD By Comparing Medial Temporal Lobe And Hippocampal Responses to 
Novel Stimuli with Functional MRI.  In addition to being a target of AD 
pathology, the hippocampus is known to express insulin receptors that might 
modulate memory performance.  Considering the role the hippocampus and related 
medial temporal lobe structures play in explicit memory function, it seems possible 
that insulin-related changes in memory performance might be reflected by increased 
activity at the medial temporal lobe particularly at the hippocampus.  It was 
hypothesized that AD subjects would exhibit increased medial temporal lobe and 
hippocampal activation to novel stimuli with insulin compared to saline.  It was 
further hypothesized that non-demented subjects would demonstrate no change in 






Summary of Results: It was found that neither the control group nor the overall AD 
group demonstrated any significant change in hippocampal or related medial 
temporal lobe activation.  The overall AD group did however demonstrate 
differences in activation between the saline and insulin conditions at several regions 
outside of the medial temporal lobe that might be linked to memory function. 
 
 
Aim 2: Determine the Role of Apolipoprotein E-epsilon-4 Genotype in Brain 
Insulin Responses.  Insulin-related memory enhancement appears to exhibit a dose-
dependent interaction across apolipoprotein E-epsilon-4 genotype in AD.  Non-
carrier AD subjects exhibit memory improvement at both 20IU and 40IU doses of 
insulin administered via nasal spray, while carriers demonstrate attenuated or 
impaired cognitive performance at the higher 40IU dose.  (M. Reger, et al., 2006) It 
was therefore hypothesized that changes in hippocampal activation during a memory 
encoding task after a single 40IU intranasal dose of insulin compared to saline would 
be greater in apolipoprotein E-epsilon-4 negative AD subjects.   
 
Summary of Results: It was found that there was an interaction in insulin related 
changes in hippocampal activation across apolipoprotein E-epsilon-4 genotype, and 
that the apolipoprotein E-epsilon-4 positive AD subjects exhibited decreased 
hippocampal activation with insulin compared to saline, predominantly on the left.  




interaction also involved the adjacent left parahippocampal gyrus. 
 
 
Aim 3: Characterize Non-Memory Related Changes in Functional MRI 
Activation in Response to Insulin.   It is not known if insulin might modulate 
specific anatomy known to possess insulin receptors, such as the hippocampus, or if 
other regions and structures might exhibit insulin-related changes in function.   To 
characterize insulin-related changes in regions unrelated to memory processes, a 
simple fMRI motor task was performed during the same scanning session as the 
memory encoding task.  It was hypothesized that motor activity would be greater 
with insulin compared to saline, but that no differences in this effect would be 
evident between the diagnosis groups. Insulin is also known to act as a vasodilator 
peripherally, (E. A. Anderson & Mark, 1993) so mean cerebral blood flow was 
assessed using arterial spin-labeled MRI.  It was hypothesized that mean cerebral 
blood flow would increase with insulin, without regard for diagnosis. 
 
 
Summary of Results: It was found that right (ipsilateral) somatosensory cortex 
demonstrated greater insulin-related activation in the apolipoprotein E-epsilon-4 
negative AD group compared to AD carriers, while no insulin-related change in  
motor cortex activity was demonstrated in the overall AD group.  Mean cerebral 




conditions in both diagnosis groups as well as the overall group. 
 
 
Aim 4: Determine Insulin’s Effects on Cognitive Performance.  Previous reports 
indicate that AD subjects, particularly those who do not carry an apolipoprotein E-
epsilon-4 allele, demonstrate improved memory performance after insulin 
administration. A brief image recall test and battery of standardized cognitive tests 
were performed to serve as a validation of the methods employed.  It was 
hypothesized that AD subjects, particularly those without an apolipoprotein E-
epsilon-4 allele, would show improved memory performance with insulin compared 
to saline.   
 
 
Summary of Results: It was found that apolipoprotein E-epsilon-4 negative AD 
subjects demonstrated greater image recall performance with insulin compared to 
saline, while no change in performance was evident in the apolipoprotein E-epsilon-
4 positive AD group, or in the overall AD or control groups.  No difference in 
performance on the standardized cognitive tests between the saline and insulin 
conditions was evident in the control or overall AD group, or in either 
apolipoprotein E-epsilon-4 subgroup. 
 




In sum, the work presented herein will lead to submission of three unique 
manuscripts for publication. 1) Hippocampal and Limbic Volume Are Related to 
Insulin Levels in Early Alzheimer’s Disease, 2) Insulin Modulates Hippocampal 
Activation During Memory Encoding in Early AD According to Apolipoprotein E-
































Insulin signaling appears to influence the synthesis of both beta-amyloid and 
neurofibrillary tangles in Alzheimer’s disease, and therefore might act as an 
important modulator of Alzheimer’s neuropathology.  Our earlier studies have 
demonstrated a positive correlation between peripheral insulin and whole brain 
volume in AD, suggesting that higher insulin may be neuroprotective.  We examined 
the relationship between peripheral insulin during a 3-hour intravenous glucose 
tolerance test and regional brain volume in early Alzheimer’s disease using voxel-
based morphometry, hypothesizing that insulin levels would correlate with volume in 
regions known to express insulin receptors, specifically at the hippocampus.  Our 
results demonstrate a positive correlation between insulin and hippocampal volume 
in AD, but not controls.  We further found a positive correlation between insulin and 
limbic/paralimbic gray and white matter volume.  Lastly, insulin positively 
correlated with hypothalamic volume in apolipoprotein E-epsilon-4 negative AD 
subjects, but not in AD subjects with the gene.  Our results suggest that insulin might 
act as an important neurotrophic factor in AD, and add to the growing body of 






Insulin’s role in peripheral glucose metabolism is well known, but a growing 
body of research suggests impaired insulin signaling may be associated with 
Alzheimer’s disease (AD). Type 2 diabetes mellitus is a risk factor for developing 
AD (Peila, Rodriguez, Launer, & Honolulu-Asia Aging, 2002) and higher peripheral 
glucose and insulin levels are reported in early AD compared to control subjects 
(Craft, et al., 1998) suggesting that altered insulin action might be a component of 
AD pathophysiology.  The majority of brain insulin is synthesized in the pancreas 
and traverses the blood-brain barrier to reach the central nervous system. (Banks, 
2004) A recent report indicates that impaired insulin secretion during mid-life may 
be a risk factor for AD in later life, (Ronnemaa, et al., 2008) further associating 
alterations in peripheral insulin signaling with AD risk.  
 
Impaired insulin action within the brain might increase AD risk by 
contributing to beta-amyloid and tau deposition. Mechanistically, brain insulin 
signaling inhibits amyloid plaque formation by modulating the transport and 
processing of amyloid fragments through the Golgi apparatus through its influence 
on glycogen synthase kinase 3a. (Phiel, et al., 2003) Insulin signaling also inhibits 
tau hyperphosphorylation, (M Schubert, et al., 2003) a key step in the formation of 




brain insulin receptors as well as their respective signaling intermediates in AD 
(Steen, et al., 2005) providing evidence at the molecular level of altered brain insulin 
signaling in AD.  It appears therefore that faulty insulin signaling mechanisms in the 
brain might be associated with AD.  Several reports suggest that augmentation of 
insulin action might modulate AD neuropathology, further linking insulin and AD 
neuropathology.  Post-mortem examination of brains of diabetics with a history of 
using both insulin and other diabetes medications showed fewer neuritic plaques 
specifically in the hippocampus, amygdala and entorhinal cortex, suggesting that 
increased insulin effects might ameliorate or retard the formation of the 
neuropathologic hallmarks of AD. (Beeri, et al., 2008) Furthermore, increased 
plasma amyloid beta 40/42 ratio has been described after extended insulin treatment 
in AD, (S Craft, et al., 2000) suggesting that insulin might shift amyloid metabolism 
toward production of the less amyloidogenic Abeta40 species.    Higher insulin 
levels however have also been speculated to contribute to AD neuropathology. 
Natural substrates of the metalloproteinase insulin degrading enzyme (IDE) include 
both insulin and amyloid beta. (James Scott Miners, 2008) Higher insulin levels 
therefore might compete with amyloid beta for degradation by IDE (I. V. Kurochkin, 







Mounting evidence therefore suggests that insulin may serve as a modulator 
of both beta amyloid plaques and neurofibrillary tangles characteristic of AD, and 
that altered brain insulin action might promote AD neuropathology. 
 
 The apolipoprotein E-epsilon-4 allele is a known AD risk factor, (Roses, 
1994, 1998; Roses & Saunders, 1994) that also appears to be associated with altered 
insulin metabolism in AD.(S Craft, S Asthana, G Schellenberg, et al., 1999) 
Cognitive changes in response to experimental insulin administration in AD (S Craft, 
S Asthana, JW Newcomer, et al., 1999; S. Craft, et al., 2000; Craft, et al., 1996; M. 
Reger, Watson, Green, Wilkinson, et al., 2008; G. Watson, et al., 2006) exhibit an 
interaction with the apolipoprotein E-epsilon-4 allele, with non-carriers showing 
performance improvements in list recall after a single 40IU dose of insulin delivered 
intranasally, whereas APOE–e4 positive AD subjects exhibit reduced cognitive 
performance at the same insulin dose. (M. Reger, et al., 2006) This effect appears to 
be AD-specific as normal participants did not exhibit the cognitive changes seen in 
the demented subjects.  The apolipoprotein E-epsilon-4 allele may therefore be an 
important factor in modifying insulin’s putative effect on brain health and 
physiology in AD.  The biochemical mechanisms underlying these observations are 
not delineated, but APOE-e4 genotype might be expected to influence any 





Neuroimaging is increasingly used to quantify whole brain, limbic and 
hippocampal volume loss (Callen, Black, Gao, Caldwell, & Szalai, 2001; Jack, et al., 
2002; Sluimer, et al., 2008) as a reflection of pathologic burden. (Borthakur, Sochor, 
Davatzikos, Trojanowski, & Clark, 2008; Clark, et al., 2008; Hall, Moore, Lopez, 
Kuller, & Becker, 2008; Zhou, et al., 2008) Neuronal insulin receptors are not 
uniformly distributed, but rather found in high concentrations in selective regions 
including the hippocampus and hypothalamus, where they may function to modulate 
neuronal survival and AD neuropathology. (Frolich, et al., 1998; Frolich, et al., 1999; 
Hoyer, 2004a; Schulingkamp, Pagano, Hung, & Raffa, 2000)  
 
Earlier we described a positive correlation between whole brain volume 
obtained from MRI data and peripheral insulin levels during a 3-hour I.V. glucose 
tolerance test in early AD. (Burns, et al., 2007)  These findings suggest that insulin 
might influence brain structure, perhaps by modulating AD neuropathology.   Our 
objective for the current study was to extend our earlier findings by determining the 
regional specificity of the peripheral insulin and whole brain volume relationship in 
AD (Burns, et al., 2007) by using a voxel-wise regional analysis.  We hypothesized 
distinct differences in the relationship between insulin and hippocampal volume 
across the control and AD groups, and that insulin levels would positively correlate 
with hippocampal gray matter volume specifically in AD subjects.  We also explored 




voxel-wise basis.  Lastly, apolipoprotein E-epsilon-4-based differences in the 




























Participants: Data from 138 (70 AD and 68 non-demented) University of 
Kansas Brain Aging Program volunteers (Burns, Cronk, et al., 2008; Burns, et al., 
2007; Burns, Mayo, Anderson, Smith, & Donnelly, 2008) were initially reviewed to 
identify those with complete IVGTT data.  MRI data were examined visually and 
excluded if excessive motion artifacts or other technical defects that might contribute 
to normalization or segmentation inaccuracies were present.   A total of 59 early AD 
patients (61% females) and 55 non-demented controls (58% females) with complete 
IVGTT and acceptable MRI data were identified.  All participants provided informed 
consent in accordance with the University of Kansas Medical Center Human 
Subjects Committee.  Subjects underwent a thorough exam, including an interview 
with a collateral source familiar with the subject to establish the presence of 
Alzheimer’s disease.  Diagnosis was based on gradual and progressive memory 
impairment and deficit in at least one other cognitive domain, (L Berg, et al., 1988) 
with particular attention to intrasubject change, rather than deviation from group 
norms. (Morris, 1997) All demented participants met the NINDS-ADRDA criteria 
for probable Alzheimer’s disease.  Disease severity was graded with the Clinical 
Dementia Rating (CDR) scale. (Morris, 1993) Participants receiving a CDR score of 
0.5 (n=46) or 1 (n=13) were included as AD subjects, whereas those scoring 0 served 
as controls.  Exclusion criteria included diabetes (defined as insulin or oral 




disorders other than AD with the potential to impair cognition, stroke, clinically 
significant depressive symptoms, abnormalities in vitamin B12 levels, positive rapid 
plasma reagin, abnormal thyroid function, or the concurrent use of psychoactive or 
investigational medications. 
 
Insulin Measurement: A three-hour intravenous glucose tolerance test 
(IVGTT) was performed at 8:30 AM after a 12-hour fast.  Blood samples for 
determination of glucose and insulin levels were collected 5 minutes before and at 1, 
3, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, and 180 minutes after delivery of a glucose 
bolus (0.3g/kg body weight). (Burns, et al., 2007) The integrated insulin response to 
the glucose challenge was calculated using the trapezoid method and reported as 
insulin area-under-the-curve (iAUC).  Although the insulin AUC measurement used 
in this study represents endogenous insulin response to an experimental glucose 
challenge, higher values are associated with higher fasting insulin levels as well as 
increased postprandial endogenous insulin production on a day-to-day basis.  Insulin 








MRI Acquisition and Image Processing: T1-weighted MRI data 
(magnetization-prepared rapid gradient echo (MPRAGE); TR=2500ms, TE=4.38ms, 
TI=1100ms, flip angle=8 degrees, field of view 256x256mm2 with 18% oversample, 
1-mm slice thickness, 1mm3 voxels) were acquired with a 3T Siemens Allegra 
scanner (Siemens, Erlangen, Germany).   
 
Statistical Analysis: Structural MRI data were segmented into gray and white 
matter maps using the VBM5 toolbox (http://dbm.neuro.uni-jena.de), an extension of 
SPM5 (Statistical Parametric Mapping, Wellcome Department of Cognitive 
Neurology, London, UK).   The final tissue maps were modulated in order to analyze 
regional volumes, and smoothed with a 10mm FWHM Gaussian kernel.   Regression 
analysis of the control and AD subgroups separately was used to test the hypothesis 
that insulin was correlated with hippocampal volume, limiting the search volume to 
the left and right hippocampi using the Wake Forest University Pick atlas tool 
(Maldjian, Laurienti, Kraft, & Burdette, 2003).   Each participant’s gray matter data 
was specified as the dependent variable, with insulin, age and sex entered as 
regressors into the model.  Statistical parametric maps were generated demonstrating 
the relationship between insulin and hippocampal gray matter volume, controlling 
for age and sex.  Differences in the relationship between insulin and hippocampal 
gray matter voles were assessed by specifying a factor (diagnosis) with two levels 




analyses, voxels correlating with insulin with a p-value < 0.05 corrected for multiple 
comparisons (false discovery rate, FDR) were accepted as significant.  
 
Whole brain statistical parametric maps were generated for the subsequent 
within-groups exploratory analysis, demonstrating the relationship between insulin 
and gray and white matter volume, while controlling for age and sex.  Any voxels 
correlating with insulin, with a more liberal uncorrected default p-value < 0.001, 
were considered significant for these analyses.  Interaction analysis was performed to 
explore group differences in the relationship between insulin and regional gray and 
white matter volume.  The gray and white matter data were again specified as 
dependent variables, with insulin, age and sex selected as regressors.  A factor (i.e. 
diagnosis group) with two levels (AD or control) was created to model interactions 
between dementia status and insulin.  Statistical parametric maps were generated to 
demonstrate differential relationships between insulin and brain volume across 
groups controlling for age and sex. Any voxels exhibiting a between-group 








Finally, interaction analysis was used to assess apolipoprotein E-epsilon-4-
based differences in the relationship between insulin and brain structure within the 
AD group.  A two level factor (carrier or non-carrier, without regard for allelic load) 
was created to model interactions between genotype and insulin.  Statistical 
parametric maps were generated to demonstrate differential relationships between 
insulin and brain volume across groups controlling for age and sex.  Any voxels 
exhibiting a between-group interaction with an uncorrected p-value <0.001 were 
considered significant.  
 
Demographic characteristics of the subjects (Table 1) were analyzed with 
SPSS 16.0 (SPSS, Chicago, USA) using the student’s t-test and expressed as mean  
SD.  Chi2 was used to test for equality of proportions.  All images are displayed at an 
uncorrected p-value of 0.01, and a minimum cluster size of 100 voxels. The peaks of 
the imaging analyses are reported in Table 2 by Talairach (x, y, z) coordinates, along 
with the computed Z-scores and cluster sizes.   
 
Sample Characteristics:  The mean age of participants was 73.7 years (SD 
6.4), with no difference between AD or control groups.  (Table 2-1) There were no 
group differences in sex distribution (chi square=0.095, df=1, p=0.76), or 3-hour 




control group. (16.52.3y vs. 15.33.4y for the AD group, t=1.908, p=0.06)  
Apolipoprotein E-epsilon-4 genotype was available for 56 of the AD subjects (26 
apolipoprotein E-epsilon-4 negative and 30 apolipoprotein E-epsilon-4 positive). 
Insulin and Hippocampal Volume:  The small volume corrected analysis 
demonstrated a positive correlation between insulin and hippocampal gray matter 
volume in the AD subjects on both the left and right, most prominently at the 
posterior right (18, -3, -12; Z = 3.24, p=0.05, FDR) hippocampus.   The interaction 
analysis demonstrated a trend towards group-wise differences in the insulin-
hippocampal volume relationship at the posterior aspect of the right hippocampus. 
(36, -37, -4, Z=3.37, p<0.001 uncorrected, p=0.12 FDR-corrected) (Figure 2-1) 
There were no regional correlations between insulin and hippocampal gray matter 
volume in the control group. 
 
Insulin and Regional Gray Matter Volume: Exploratory whole-brain analysis 
of the AD group demonstrated a positive correlation between insulin and limbic gray 
matter volume including the cingulate gyri, both insulae and the right medial 
temporal lobe, with a global peak at the left insula (-42, 3, 0; Z = 4.11, p<0.001 
uncorrected) (Figure 2-2).  In controls, a positive correlation between insulin and 
gray matter was identified at a few scattered foci in the right occipital and left frontal 
lobes, with the greatest correlation in the right occipital region (41, -84, 3; Z = 3.46, 




correlation between insulin and gray matter volume, most prominently at the right 
parahippocampal gyrus (37, -51, -6; Z = 4.19, p<0.001 uncorrected) (Figure 2-2) 
where a positive correlation was present in the AD group but not in the controls. A 
cluster of 541 voxels located within the right pre-motor region (44, 1, 51; Z = 3.86, 
p<0.001 uncorrected) demonstrated a negative correlation with insulin in the control 
group (not shown).  Voxels with positive correlations between insulin and gray 
matter volume (p-values< 0.001, uncorrected for multiple comparisons) are listed in 














Insulin and Regional White Matter Volume: Results of exploratory analysis 
of the insulin-white matter volume relationship paralleled the insulin-gray matter 
volume relationships. The control group showed several small, isolated clusters in 
the right posterior temporal lobe region that correlated with insulin, most 
prominently at the right occipital lobe (29, -56, -15; Z = 3.51, p<0.001 uncorrected).  
The AD group however showed an extensive positive correlation between insulin 
and paralimbic white matter, most prominently at the right posterior temporal lobe 
(36, -52, 3; Z = 3.98, p<0.001 uncorrected) (Figure 2-3). Interaction analysis 
confirmed group differences in the correlation between insulin and white matter 
volume, most prominently near the right cuneus (19, -75, 13; Z = 3.97, p<0.001 
uncorrected) (Figure 2-3), where a positive correlation was present in the AD group 
compared to the controls.   No negative correlations between white matter volume 
and insulin were present.  Voxels with positive correlations between insulin and 
white matter volume (p-values < 0.001, uncorrected for multiple comparisons) are 
listed in Table 2-2.      
 
Apolipoprotein E-epsilon-4-based differences in the insulin-brain structure 
relationship: We first assessed apolipoprotein E-epsilon-4-based differences in the 
relationship between insulin and gray matter volume, again restricting the search 
volume to the hippocampus with the Wake Forest University Pick atlas.   This 




at the hippocampus.  Voxel-wise while brain analysis of apolipoprotein E-epsilon-4-
based differences in the relationship between insulin and gray matter however 
revealed an interaction at two locations (8, -1, -3 and -7, -3, -5; p<0.001 uncorrected) 
where a positive correlation was present in the apolipoprotein E-epsilon-4 negative 
AD but not in the apolipoprotein E-epsilon-4 positive AD group. (Figure 2-4)  The 
corresponding Talairach coordinates map to the hypothalamus. Comparing the 
apolipoprotein E-epsilon-4 positive to the apolipoprotein E-epsilon-4 negative AD 
group revealed no voxels where the insulin-gray matter correlation was greater in the 
apolipoprotein E-epsilon-4 positive AD group compared to the apolipoprotein E-









We reported earlier that peripheral insulin positively correlated with whole 
brain volume in early AD. (Burns, et al., 2007)  The current study extends our earlier 
findings by demonstrating an AD-specific relationship between insulin and 
hippocampal volume.  Our exploratory analysis of regional gray and white matter 
furthermore demonstrates that higher peripheral insulin levels are associated with 
higher gray and white matter volume in limbic and paralimbic structures, regions that 
bear significant pathologic burden in AD.  Although the specific mechanism 
underlying our observations cannot be determined from this study, our results are 
consistent with other studies suggesting attenuation of AD neuropathologic burden in 
those brain areas known to express insulin receptors and to bear a large pathologic 
burden in AD (Beeri, et al., 2008; S. Craft, et al., 2000; Phiel, et al., 2003; M 
Schubert, et al., 2003)  Alternatively, insulin might act specifically on insulin-
sensitive limbic anatomy to exert neurotrophic effects. (Craft & Watson, 2004; 
Francis, et al., 2008; Gasparini & Xu, 2003; M. Schubert, et al., 2004) 
 
Our findings may also represent attenuation of atrophy rates in insulin-
sensitive regions in subjects with higher insulin levels.  In sum, these findings 
suggest that higher insulin exposure in AD might modulate the progression of 




argument.     
 
Although we did not find Apo-e4 related differences in the relationship 
between insulin and hippocampal volume, our whole-brain analysis identified an 
interaction across apolipoprotein E-epsilon-4 groups in the hypothalamus, with a 
positive relationship between insulin and hypothalamic gray matter volume in 
apolipoprotein E-epsilon-4 negative AD subjects that was not present in the 
apolipoprotein E-epsilon-4 positive group.  This is particularly interesting given the 
central role of the hypothalamus in endocrine control including regulating insulin 
secretion. (Bobbioni-Harsch & Jeanrenaud, 1990)  It is not clear from this cross 
sectional study if higher insulin levels contribute to preserved hypothalamic volume 
in apolipoprotein E-epsilon-4 negative AD, or if greater hypothalamic volume is 
associated with greater insulin response to the glucose challenge in these subjects.  
These findings suggest that insulin might exert beneficial neurotrophic effects at the 
hypothalamus in apolipoprotein E-epsilon-4 negative AD, and add to the growing 
body of evidence that the apolipoprotein E-epsilon-4 allele is an important 







Since the cross-sectional design limits the inferences that can be made from 
this study, our findings need confirmation in longitudinal and interventional trials to 
establish if insulin influences regional brain atrophy rates in AD. Although we used 
sensitive and validated clinical methods to identify subjects with the earliest stage of 
Alzheimer’s disease, (Morris, 1997) postmortem examination is the most accurate 
method of diagnosis.  The findings in the white matter of AD patients in particular 
should be interpreted with caution as these might be related to periventricular white 
matter changes that have the potential for misclassification in VBM. (Levy-
Cooperman, Ramirez, Lobaugh, & Black, 2008) Although the optimized method we 
used reduces such error, (Good, et al., 2001) systematic misclassification of white 
matter lesions as gray matter in the AD group might lead to over-modulation of 
adjacent white matter regions, generating fictitious regional white matter atrophy in 
AD.  Lastly, we used peripheral measures of insulin as a surrogate measure for CNS 
insulin.  Although insulin within the CNS is derived primarily from the periphery, 
(Banks, 2004) peripheral values may not accurately reflect CNS insulin levels as the 















Age (years) 73.13 (6.19) 74.29 (6.55) 0.33 
Education (years) 16.35 (2.29) 15.32 (3.37) 0.06 
MMSE 29.44 (0.76) 26.27 (3.64) <0.001 

















Table 2-2. Summary of Suprathreshold Peaks.  Brodmann areas and location 
names were determined from the Talairach Client after converting the MNI 





Area/Location MNI Coordinates 









41, -84, 3 3.46 316 










-42, 3 0 4.11 4.11 2579 
    6 -27, 4, 47 3.61 168 
    21 -62, -4, -13 3.56 161 
    Left LFN -10, 1, 5 3.78 103 
    31 3, -44, 29 3.43 400 
    21 -68, -30, -1 3.38 101 
    13 40, 5, -2 3.38 121 
    19 42, -74, -6 3.38 115 





36, -52, 3 3.98 2328 
    Left PHG -20, -35, -9 3.83 1252 
      19, -52, 13 3.74 572 
    Right CG 14, -20, 36 3.70 632 
    Left Frontal Lobe -39, 23, 3 3.69 117 
    Left Frontal Lobe -25, -34, 21 3.59 288 
 




Figure 2-1-Peripheral Insulin and Hippocampal Gray Matter Volume. 
 
Peripheral insulin during a 3-hour IVGTT correlated with gray matter volume at the 
hippocampus in AD (A, p=0.05 FDR) but not in controls.  Interaction analysis (B) 
confirmed group differences in the relationship between insulin and hippocampal 
volume.  The yellow cluster in B denotes where the positive correlation between 
insulin and hippocampal volume in AD was significantly different from controls. 
(p=0.09 FDR, p<0.001 uncorrected) The search volume was restricted to the 











Figure 2-2-Regional Relationships Between Insulin and Gray matter Volume.   
Control subjects demonstrated a relationship in several scattered regions including 
the occipital lobe (A), while an extensive limbic/paralimbic relationship was present 
in the AD group.  Interaction analysis confirmed these group-wise differences, most 
significantly at the right parahippocampal region (C) These whole-brain analyses 













Figure 2-3-Regional Relationships Between Insulin and White Matter Volume.   
 
Control subjects demonstrated a relationship in several scattered regions including 
the frontal and occipital lobes. (A) Similar to the gray matter findings, the AD group 
showed an extensive limbic/paralimbic relationship with insulin. (B) Interaction 
analysis confirmed these group-wise differences. (C)  These whole-brain analyses 














Figure 2-4-APOE-e4-Related Differences in The Relationship Between Insulin 









There was a significant difference in the relationship between insulin and 
hypothalamic gray matter volume across APOE-e4 genotype, with greater insulin 
levels associated with greater hypothalamic volume in APOE-e4 negative AD.  This 













Chapter 3-Insulin Modulates Hippocampal Activation During Memory Encoding in 




















Insulin Modulates Hippocampal Activation During Memory Encoding in Early AD 




 Several descriptions of insulin-related memory improvement in early 
Alzheimer’s disease subjects suggest that this hormone might modulate brain 
function.  Insulin’s effect on memory furthermore appears to differ according to 
apolipoprotein E-epsilon-4 genotype in AD with greater memory improvement in 
non-carriers.  The neural substrates of this phenomenon are not clear, however the 
hippocampus is known to express insulin receptors that might influence memory 
processes.  Modulation of hippocampal function by insulin might therefore be 
involved in insulin-related memory facilitation in Alzheimer’s disease.  The goal of 
this study was to characterize changes in hippocampal activation after insulin 
administration using functional MRI during a memory encoding task.  It was 
hypothesized that hippocampal activation would be greater during the memory 
encoding task with insulin compared to saline in Alzheimer’s disease subjects, 






The results demonstrated an AD-specific interaction in hippocampal activation 
between the saline and insulin conditions across apolipoprotein E-epsilon-4 
genotype.  The apolipoprotein E-epsilon-4 negative AD subjects exhibited increased 
image recall performance with insulin compared to saline, which positively 
correlated with insulin-related changes in hippocampal percent activation volume.  
Image recall performance in demented carriers of the apolipoprotein E-epsilon-4 
allele was similar between the saline and insulin conditions, but this group showed a 
significant decrease in hippocampal percent activation volume after insulin 
administration.   
 
These results suggest that insulin might act at the hippocampus in 
apolipoprotein E-epsilon-4 positive AD subjects to promote cognitive function 
described herein and by others.  The observation of insulin-related decrease in 
hippocampal percent activation volume along with constant image recall 
performance seen in the apolipoprotein E-epsilon-4 positive AD group might 
indicate increased hippocampal efficiency in this subgroup.  The interaction in 
hippocampal percent activation volume across apolipoprotein E-epsilon-4 genotype 
in AD subjects suggests that this allele defines two AD subpopulations with 






Converging evidence implicates defective insulin signaling in Alzheimer’s 
disease (AD) pathogenesis (Benedict, et al., 2007; Craft, 2006; S Craft, et al., 2000; 
Craft, et al., 1998; Hoyer, 2004a, 2004b; Jones & Leonard, 2005; Kim, et al., 2006; 
Messier & Teutenberg, 2005a; van der Heide, Hoekman, Biessels, & Gispen, 2003).  
Altered insulin signaling for example has been shown to contribute to AD 
neuropathology. (Hoyer, 2004a, 2004b; Kim, et al., 2006; van der Heide, et al., 
2003) Non-diabetic AD patients also may exhibit higher peripheral glucose and 
insulin levels, a profile similar to that seen in type 2 diabetes. (Craft, et al., 1998)  A 
recent report indicates that impaired insulin secretion during mid-life may be a risk 
factor for AD in later life, (Ronnemaa, et al., 2008) and type 2 diabetics are at 
increased AD risk, (Peila, et al., 2002) further suggesting an association between 
insulin dysregulation and AD.   
 
The role of insulin in brain health and function is currently not fully 
delineated, but insulin may have a modulatory role in memory function.  For 
example, injection of insulin into the cerebral ventricles of rats improves memory. 
(Park, Seeley, Craft, & Woods, 2000)  Furthermore, intraventricular injection of 
streptozotocin, which interferes with insulin signaling mechanisms, leads to 




be linked to memory function at the molecular level.  The majority of brain insulin is 
formed in the pancreas and traverses the blood-brain barrier to reach the central 
nervous system, (Banks, 2004) where insulin receptors are found in high density in 
specific regions including the olfactory bulbs, hypothalamus and the hippocampus. 
Neuronal insulin signaling at the hippocampus promotes the phosphorylation and 
mobilization of intracellular stores of AMPA receptors, increasing their surface 
expression on post-synaptic membranes. (Ahmadian, et al., 2004; Man, et al., 2000; 
Trudeau, et al., 2004) Insulin signaling also promotes phosphorylation and increased 
activity at NMDA receptors. (Christie, et al., 1999)  Thus, neuronal insulin signaling 
might be linked to cognitive function via modulation of long-term depression (LTD) 
and long term potentiation (LTP) mechanisms specifically at the hippocampus.   
 
Insulin’s potential role in cognitive function, particularly in AD, is supported 
by several reports of memory improvement after exogenous insulin administration. 
Intravenous injection of insulin in AD subjects, along with dextrose to maintain 
glucose at baseline levels, increases CSF insulin levels and acutely improves 
performance on cognitive tasks such as list and word recall.  (S Craft, S Asthana, JW 
Newcomer, et al., 1999; Craft, et al., 1996)  Insulin administration via nasal spray 
has been shown to promote cognitive performance in AD similar to IV 
administration, without hypoglycemia risk. (M. Reger & S. Craft, 2006; M. Reger, et 




Wilkinson, et al., 2008)  Insulin administered in this manner appears to travel along 
the outside of trigeminal nerves via bulk flow to access the CSF, bypassing the 
bloodstream.  (Thorne, et al., 2004) The memory effects of insulin appear to be most 
pronounced in APOE-4 negative AD subjects, (Bassett, et al., 2006; Craft, et al., 
1998; Kukull, et al., 1996; Mosconi, et al., 2004; Pedersen, et al., 2006; M. Reger, et 
al., 2006; M. A. Reger & S. Craft, 2006; Risner, et al., 2006; G. Watson, et al., 2005) 
suggesting that the apolipoprotein E-epsilon-4 allele might interact with insulin 
signaling to modulate memory facilitation. 
 
 The anatomic structures mediating insulin’s cognitive effects are unknown, 
however the hippocampus is a likely substrate.  In addition to being a target of AD 
pathology, hippocampal neurons express insulin receptors that might influence 
memory performance.  Insulin treatment has been shown to lead to transient 
phosphorylation of tyrosine residues of NR2A and NR2B NMDA receptor subunits 
in rat hippocampus. (Christie, et al., 1999) Insulin-related facilitation of NMDAr 
activity in xenopus oocytes has also been described.  (Liu, Brown, Webster, 
Morrisett, & Monaghan, 1995)  Long-term potentiation was found to be impaired in 
diabetic rats hippocampus, but this function was restored with insulin treatment. 
(Izumi, Yamada, Matsukawa, & Zorumski, 2003) Insulin therefore appears to play a 
role in NMDA activity and hippocampal long-term potentiation mechanisms that 




 The primary goal of this pilot study was to characterize hippocampal responses 
to insulin in early AD, and secondarily to assess the role of apolipoprotein E-epsilon-
4 genotype in modulating hippocampal insulin responses.  We hypothesized that 
early AD subjects would exhibit increased hippocampal activity during a memory 
encoding task with insulin compared to saline placebo.  We furthermore 
hypothesized that insulin would have a greater effect on hippocampal activity in 
apolipoprotein E-epsilon-4 negative AD subjects, paralleling reports of differential 
insulin memory effects along apolipoprotein E-epsilon-4 genotype in AD.  We also 
performed a battery of standardized cognitive tests to replicate earlier reports and 














Subject Selection: All participants were right-handed non-diabetics over the 
age of 60, and provided written informed consent in accordance with the University 
of Kansas Medical Center Human Subjects Committee. Diagnostic criteria for AD 
included gradual and progressive memory impairment and deficit in at least one 
other cognitive domain. (L. Berg, et al., 1988) A thorough exam, including an 
interview with a collateral source familiar with the subject, was performed to 
characterize the presence and severity of dementia with the Clinical Dementia Rating 
(CDR) scale, (Morris, 1993) focusing on intrasubject change rather than deviation 
from group norms. (Morris, 1993, 1997; Rockwood, Strang, MacKnight, Downer, & 
Morris, 2000) Participants included AD subjects with CDR scores of 0.5 and 1, 
while those with CDR scores of 0 served as controls.  Exclusion criteria (Burns, et 
al., 2007) included diabetes (defined as self-reported insulin or oral hypoglycemic 
agent use, or fasting blood glucose > 126 mg/dl), disorders other than AD with the 
potential to impair cognition, stroke, clinically significant depressive symptoms, 
abnormalities in vitamin B12 levels, positive rapid plasma reagin, abnormal thyroid 
function, or concurrent use of psychoactive or investigational medications. 
Apolipoprotein E-epsilon-4 genotype in the AD subjects was determined by allelic 
discrimination. Participants were not excluded from this pilot study if they were 





All participants were scanned on two occasions at least 48 hours apart in a 
double-blind, crossover, and counterbalanced manner. All scanning was performed 
in the morning after an overnight fast.  Participants were instructed to take any 
morning medications as usual, and to maintain their usual caffeine intake on study 
days.  For each visit, either 40IU insulin aspart, (Benedict, et al., 2007) or an equal 
volume of saline placebo, was administered via nasal spray.  (M. A. Reger & S. 
Craft, 2006) An IV line was placed prior to insulin administration for pre- and post-
drug/placebo glucose and insulin testing, and for ready vascular access for dextrose 
infusion if necessary due to hypoglycemia.  Subjects were shown a brief video for 
familiarization with the fMRI tasks.   
 
 Imaging: A Siemens 3T Allegra scanner using a quadrature head coil was used 
for all imaging.  A T1-weighed image (Magnetization-Prepared Rapid Gradient Echo 
[MPRAGE]; TR=2500 ms, TE=4.38 ms, TI=1100ms, flip angle=8 degrees, field of 
view 256x256mm with 18% oversample, slice thickness/gap/number=1mm/0/208) 
was acquired to provide a backdrop on which to overlay functional data, and to 
provide anatomic information for hippocampal mask creation. Blood-oxygen level 
dependent (BOLD) sensitive EPI data were acquired parallel to the AC-PC line. 
(FOV=192x100, slice thickness/gap/number=3.0mm/0.5mm/43, TR=3000, TE=40, 





 Memory Encoding Stimulus: The 10 minute memory encoding stimulus 
consisted of alternating blocks of novel and repeated image groups, separated by 
fixation blocks of equal duration. (Golby, et al., 2005)  Each block of novel stimuli 
consisted of 8 unique images (6 outdoor and 2 indoor scenes) presented for 2500ms 
(with 500 ms interstimulus gap) in a pseudorandom order (total block duration = 24 
seconds).  To ensure active task engagement, subjects were instructed to respond by 
button press when presented with an outdoor scene.  The phrase “Outdoors?” was 
placed unobtrusively at the lower margin of each image to remind participants of the 
task.  The repeated stimulus blocks were composed of a single outdoor image 
displayed 6 times along with a single indoor image, displayed twice in a 
pseudorandom order with the same timings, durations and response instructions as 
for the novel stimuli blocks.  A white cross on a black background was displayed 
during the fixation blocks.  Subjects were visually cued to press the response button 
6 regularly spaced times during the fixation blocks, keeping the number of expected 
button presses (6) equal across all blocks of the stimulus.  The order of novel and 
repeat block presentation was counterbalanced between sessions, and different image 
sets were shown for each visit. Stimuli were presented with commercial software 
(Presentation, NeuroBehavioral Systems) using an LCD back projection system with 
MRI-compatible vision correction when necessary.  Images used for the memory 
encoding stimulus were obtained from commercially available sources (Corel, Inc.) 





  Region-of-Interest Based Functional MRI Data Analysis: We chose to 
characterize hippocampal activation in each individual for each session as 
hippocampal percent activation volume (HPAV) using an anatomically-based 
region-of-interest (ROI) approach.  Since brain atrophy has been shown to influence 
fMRI activation, (Brodtmann, Puce, Darby, & Donnan, 2009) our goal was to 
minimize the potentially confounding influence of hippocampal volume variability 
related to intersubject differences and AD-related atrophy. (Figure 3-1) The first step 
in HPAV calculation required the creation of left and right hippocampal masks based 
on the T1 data from each session using established protocols. (Burns, et al., 2007; 
Jack, et al., 1999) The tracings were done with an 8x6 inch digitizing tablet by a 
single operator. (GPT)   Volumes for the left, right and total hippocampal masks 
were calculated for each subject/session by multiplying the number of mask voxels 
by voxel volume.  
 
 The functional data was next processed and analyzed with SPM5 (Wellcome 
Trust Centre for Neuroimaging, University College London).  The first 6 seconds of 
functional data were discarded to allow for image stabilization.  The BOLD data 
underwent slice-timing correction, 3D motion correction and smoothing with a 4mm 
isotropic Gaussian kernel.  Voxel-wise linear regression analysis of the fMRI data 
employing a canonical hemodynamic response function and serial correlation 




restricting the analysis to each hippocampus with the subject-and-session-specific 
hippocampal masks. The motion correction parameters were included as covariates 
to account for motion-related signal variance.  Voxels surviving this single 
subject/session analysis at a threshold of p<0.05 uncorrected for multiple 
comparisons were considered active. Activation volumes for the left, right and total 
hippocampus were calculated by multiplying the number of active voxels by fMRI 
voxel volume.  HPAV was then calculated by dividing the activation volume from 
the fMRI analysis by total hippocampal mask volume.  Thus, left, right and total 
hippocampal percent activation volume was calculated for each subject in both the 
saline placebo and insulin conditions.   
 
 Whole brain functional analysis (BrainVoyagerQX) was also performed to 
explore insulin effects outside of the hippocampus.  T1-weighted data were re-
sampled into 1x1x1 mm isometric voxels in a sagittal orientation and manually 
warped into a common stereotactic space. (Talairach & Tournoux, 1988)  The first 
few seconds of fMRI data were discarded to allow for image stabilization.  
Processing of the fMRI data began with sync-interpolated slice timing correction, 
followed by trilinear 3D motion correction, high-pass temporal filtering (128 sec), 
smoothing with a 4mm FWHM Gaussian filter, and warping into stereotactic space. 
(Talairach & Tournoux, 1988) Voxel-wise linear regression analysis of the fMRI 




correction was used to characterize regions engaged in memory encoding by 
comparing BOLD signal in the novel blocks to fixation.    A random effects model 
was used to characterize whole brain responses in the insulin condition to that of 
saline in both the control and overall AD groups, as well as across apolipoprotein E-
epsilon-4 genotype in the AD subjects.   Voxels within the hippocampus and related 
medial temporal lobe anatomy were considered active if their BOLD time course 
exhibited a positive or negative correlation with the expected response at p<0.001, 
uncorrected for multiple comparisons.  Interactions in BOLD response across 
apolipoprotein E epsilon-4 genotype were considered significant at p<0.001 
uncorrected for multiple comparisons as well.  Anatomic location and Brodmann 
classification of activated voxels were characterized with the Talairach Client 
(www.talairach.org). 
 
 Cognitive Testing: A brief test of image recall was performed at the end of the 
scanning session before subjects were removed from the scanner.  A total of 30 
images were displayed, (2500 milliseconds each with a 500 millisecond interstimulus 
gap) 20 of which were previously presented during the fMRI memory stimulus, 
using the same LCD back projection system.  Image recall scores were calculated by 
subtracting the total number incorrect responses from the total correct.  Outside the 
scanner, a single rater (GPT) administered a battery of standard cognitive test 




Memory I and II, (Wechsler, 1955)) Free and Cued Selective Reminding Task, 
(Grober, 1988)) working memory (Wechsler Adult Intelligence Scale [WAIS] letter–
number sequencing (Wechsler, 1955)), executive function (Trailmaking A and B, 
(34) Verbal Fluency (Hanninen, et al., 1994) [animals, letters R/S and B/L], and 
visuospatial ability (WAIS Block Design (Wechsler, 1955)). The Mini-Mental State 
Examination (MMSE) (Folstein, Folstein, & McHugh, 1975) was used as an 
assessment of general cognition.  Individual cognitive performance scores were z-
transformed to the overall group mean.  The z-transformed scores from similar 
cognitive domains were then averaged together to create scores for memory, working 
memory, executive function, visuospatial processing.  Individual global cognitive 
performance was represented by the mean of all z-transformed scores. 
 
 Statistical Analysis: Group differences in age, weight, education, fasting 
glucose, insulin levels and baseline/saline hippocampal percent activation volume 
were assessed with the Kruskal-Wallis test, while the chi-square test was used to 
characterize proportions of non-continuous data between groups. The binomial test 
was used to assess the integrity of blinding with regards to drug administration, as 
well to assess adequate performance of the task during fMRI scanning.  Change in 
plasma glucose and insulin levels, as well as hippocampal percent activation volume 
between the placebo and insulin conditions was assessed with the Wilcoxon Signed 




differences in changes in hippocampal percent activation volume between the saline 
and insulin conditions.  All statistical analyses outside of imaging space were 




 A two-sided, two-sample t-test with =0.05 will have 70% power to detect an 
effect size (|1-2|/) of 1.0 with this sample of 20 subjects with AD and 10 non-
demented controls.  Similarly, this sample size will have 80% and 90% power to 
detect effect sizes of 1.12 and 1.30, respectively.  This power will likely be reduced 
if the nonparametric Wilcoxon signed rank test is required for this primary aim 












Sample Characteristics (Table 3-1): Ten cognitively intact and 18 early AD 
subjects participated in this study.  Eleven of the early AD subjects were 
apolipoprotein E-epsilon-4 carriers.  The overall control and AD groups were similar 
in age, education level, and fasting glucose and insulin levels, although there was a 
trend towards greater body weight in the AD group compared to the controls.  
Hippocampal percent activation volume in the saline condition was also not 
statistically different between the control and overall AD group.  Demented subjects 
expectedly exhibited lower global cognitive scores.  The sex distribution of the 
control and AD groups were marginally different, (chi-square=4.68, df=1, p=0.05) 
with 70% females in the control group, and 28% females in the AD group.  
Participants were not able to identify the order of drug administration at a rate 
greater than chance (observed proportion correct in the overall group was 0.18, 
p=0.001).  The apolipoprotein E-epsilon-4 carriers and non-carriers in the AD group 
were also similar in terms of baseline cognitive performance, age, weight, fasting 
glucose, educational attainment and HPAV.  There were however no female 







Plasma Glucose: Plasma glucose showed a slight trend towards lower values 
with insulin in the overall group from 90.7 mg/dl prior to, and 88.7 mg/dl after 
insulin administration. (p=0.07) None of the participants experienced any 
hypoglycemia symptoms.  
 
Insulin and Cognitive Performance: The apolipoprotein E-epsilon-4 negative 
AD group showed improved image recall scores with insulin compared to saline. 
(mean change  = 4, SD 4.16, p=0.05)  (Figure 3-2) Neither the apolipoprotein E-
epsilon-4 positive AD group nor the control groups demonstrated any change in 
image recall between the saline and insulin conditions.  No insulin-related change in 
performance on the standardized cognitive tests was noted in the control, overall AD 
or AD apolipoprotein E-epsilon-4 groups.  There was however a negative correlation 
between performance on the standardized testing and the time delay between insulin 
administration and the tests, but only in the AD group (Global cognitive score; 
Pearson correlation -0.734, p=0.001).  No similar relationship between drug 








Hippocampal Percent Activation Volume: Review of logged key responses 
during the memory encoding task showed that all participants performed at a level 
greater than chance. (i.e.>50% correct responses) during the fMRI memory stimulus 
under both the saline (26 out of 28 participants responded correctly >50% of trials, 
p=0.00) and insulin (26 out of 28 participants responded correctly >50% of trials, 
p=0.00) conditions.  Hippocampal percent activation volume (HPAV) in the saline 
condition was not statistically different between the control (17.24%, SD 15.85), 
apolipoprotein E-epsilon-4 negative (9.07% SD 6.12) and apolipoprotein E-epsilon-4 
positive AD (16.54% SD 10.66) groups. (chi-square=2.02, df=2, p=0.36)    
 
Insulin-related changes in HPAV are presented in Table 3-2.   The control 
subjects exhibited a trend towards greater HPAV with insulin (21.4%, SD 13.9) 
compared to saline (17.32, SD 15.9, p=0.074), while HPAV in the overall AD group 
was not statistically different between the insulin (8.5%, SD 6.2) and saline (13.6%, 
SD 9.7) conditions (p=0.15).  HPAV in the apolipoprotein E-epsilon-4 negative AD 
subjects was not statistically different between the insulin (12.2%, SD 7.5) and saline 
(9.1%, SD 6.1) conditions (p=0.31), while apolipoprotein E-epsilon-4 positive AD 
subjects exhibited decreased HPAV with insulin ( 6.1&, SD 4.1) compared to saline 
( 16.5%, SD 10.7, p=0.03).  (Figure 3-2)  Apolipoprotein E-epsilon-4 based 




group were confirmed with the Mann-Whitney U test (Mann-Whitney U=15.00, 
p=0.03) 
 
Whole Brian fMRI Analysis: Insulin administration did not alter medial 
temporal lobe activation during the memory task in the control or overall AD group, 
consistent with the ROI results. In the overall AD group however there was greater 
BOLD signal in several locations with insulin compared to saline. (Figure 3-3, Table 
3-3)  These included the anterior cingulate gyrus and prefrontal cortex. Comparing 
BOLD signal between the saline and insulin conditions across apolipoprotein E-
epsilon-4 genotype in the AD group revealed significant differences in functionally 
related regions that included the left parahippocampal gyrus, left and right precuneus 












The goal for this study was to characterize changes in hippocampal activation 
in response to insulin in early AD, with the hypothesis that hippocampal activity 
would be greater during a memory-encoding task with insulin compared to saline.  It 
was further hypothesized that insulin-related changes in hippocampal activity would 
be greatest in apolipoprotein E-epsilon-4 negative AD subjects.  Our ROI-based 
assessment of hippocampal percent volume activation (HPAV) revealed distinct 
differences in hippocampal insulin responses based on apolipoprotein E-epsilon-4 
genotype in the AD subjects.  Carriers of this AD risk factor gene exhibited 
decreased HPAV with insulin compared to saline during the fMRI memory encoding 
task, while non-carriers showed no statistically significant change in HPAV with 
insulin compared to saline.  This apolipoprotein E-epsilon-4 genotype based 
interaction was supported with the whole-brain fMRI analysis, which revealed 
increased left parahippocampal gyrus activation during the memory stimulus 
between the saline and insulin conditions in non-carriers compared to carriers.   
 
Image recall performance was improved with insulin in apolipoprotein E-
epsilon-4 negative AD subjects in line with earlier reports.  These changes correlated 
with HPAV in this group, linking insulin related changes in cognitive performance 




was interesting that no insulin-related changes in performance on the standardized 
cognitive testing was noted, but the negative correlation between scores on these 
tests and the time delay between insulin administration and testing in AD suggests 
that insulin might have a short-term effect on memory in AD. 
 
Increased activation was also noted in the overall AD group with insulin 
compared to saline in several prefrontal regions as well as the anterior cingulate 
gyrus, areas functionally related to hippocampal function and explicit memory 
encoding, suggesting that modulation of these regions by insulin might also 
contribute to the memory facilitation seen in AD in general.     
 
The mechanism underlying insulin’ effects on neural memory function are 
not currently known.  Insulin might directly modulate LTP/LTD mechanisms via 
specific hippocampal insulin receptors as described earlier.  Alternatively, insulin 
signaling might augment oxidative metabolism by promoting the phosphorylation of 
hexokinase and phosphofructokinase.  These enzymes catalyze the initial steps of 
glycolysis, committing glucose to ATP production. (Hoyer, 2004b) Additionally, 
other non-specific physiologic effects might also contribute to insulin’s effect on 
memory.  Insulin administration has been shown to increase CSF norepinephrine 




2006) Norepinephrine acts to increase cortical excitability by inhibiting slow acting 
potassium channels, and might therefore be expected to increase neuronal firing 
rates, which might increase task attention and performance.  Insulin also acts as a 
vasodilator peripherally, (E. A. Anderson & Mark, 1993) and such an effect on 
cerebral blood flow, resulting in increased delivery of glucose and oxygen, might be 
expected to contribute to improved cognitive performance.   
 
How any of these mechanisms might interact with apolipoprotein E-epsilon-4 
genotype in their potential effect on neural function or cognitive performance 
however is not clear.  The distinct difference in hippocampal insulin responses across 
apolipoprotein E-epsilon-4 genotype in AD suggests that these two sub-populations 
might exhibit fundamental differences in brain insulin sensitivity in AD.  It is 
interesting to note that apolipoprotein E-epsilon-4  negative AD are at increased risk 
for type 2 diabetes and overweight, (Profenno & Faraone, 2008)  providing evidence 
of peripheral insulin signaling disparities across apolipoprotein E-epsilon-4 
genotype. Although the biochemical reasons for this genetic-based difference in 
insulin brain responses cannot be determined from our study, apolipoprotein E-
epsilon-4 genotype in AD nevertheless appears to be an important consideration 
when assessing insulin effects on both memory and brain activity in AD, and might 





Several factors must be considered when interpreting our results.  The BOLD 
signal used in fMRI studies is an indirect estimate of underlying neuronal activity.  
The first link in the chain of events leading to “activation” is the coupling of regional 
blood flow to neuronal activity.  This neurovascular coupling has been shown to 
exhibit altered temporal characteristics in older adults contributing to reduced signal-
to-noise ratio, (D'Esposito, Deouell, & Gazzaley, 2003) and complicating 
interpretation of functional imaging in this demographic.  Furthermore, 
cholinesterase inhibitors used to treat AD exhibit significant vascular effects 
independent of neural activity. (D'Esposito, et al., 2003; Rosengarten, Paulsen, Burr, 
& Kaps, 2008) Most of the AD participants in this pilot study were taking 
cholinesterase inhibitors, which might have interacted with insulin to alter BOLD 
signal.  Additionally, insulin itself is known to act as a vasodilator peripherally, (E. 
A. Anderson & Mark, 1993) and thus might alter BOLD-based imaging.  Further 
complications arise from the atrophy seen in AD, which reduces the volume of tissue 
capable of generating BOLD signal.   For this reason, we specifically avoided 
directly comparing the control and AD groups in imaging space, although the ROI-
based hippocampal percent volume activation measurement we used should account 







In summary, our results add to the growing body of research focusing on 
insulin signaling in early AD by providing evidence that insulin modulates 
hippocampal function and cognitive performance in early AD according to 
apolipoprotein E-epsilon-4 genotype.  Thus it seems that these two groups should not 
be combined in studies of insulin in early AD.  These observations further suggest 
that insulin signaling mechanisms might serve as a novel therapeutic target for a 















Table 3-1-Sample Characteristics 
  Normal (n=10) Early AD (n=18) p-value 
Global Cognition (Z-score) 0.5 (0.4) -0.3 (0.8) <0.001 
Percent Female 70% 28% 0.05 
Age (years) 73.6 (6.3) 72.6 (7.8) 0.72 
Weight (pounds) 149.8 (29.8) 171.9 (28.9) 0.07 
Fasting Glucose (mg/dl) 97.9 (12.8) 93.3 (9.3) 0.28 
Education (years) 16.4 (2.7) 15.7 (4.2) 0.66 
Total HPAV (%) Saline 17.2 (15.6) 13.6 (9.7) 0.53 
 



















AD (n=11) p-value 
Global Cognition (Z-score) 0.5 (0.4) -0.3 (0.8) 0.82 
Percent Female 0% 46% 0.04 
Age (years) 73.6 (6.3) 72.6 (7.8) 0.75 
Weight (pounds) 149.8 (29.8) 171.9 (28.9) 0.39 
Fasting Glucose (mg/dl) 97.9 (12.8) 93.3 (9.3) 0.86 
Education (years) 16.4 (2.7) 15.7 (4.2) 0.46 
Total HPAV (%) Saline 17.2 (15.6) 13.6 (9.7) 0.11 
 













Table 3-3. HPAV with saline and insulin by Group.  The control group exhibited 
a trend towards greater HPAV with insulin compared to saline.  The APOE-e4 










 Saline Insulin p-value
Control (n=10) 17.24% (15.85 21.43% (13.87) 0.07 
Early AD (n=18) 13.64% (9.70) 8.48% (6.24) 0.15 
APOE-e4 neg. AD 9.07% (6.12) 12.16% (7.50) 0.31 




Table 3-3-Insulin Effects in Overall AD Group During Memory Encoding Task.  














Lobe Landmark X Y Z 
Brodmann 
Area 







55 -26 21 40 4.29 311 
Rt. Occipital 
Lobe 
Cuneus 20 -80 4.9 17 5.45 467 
Rt. Limbic Lobe 
Anterior 
Cingulate 
8.8 33 17 24 5.26 487 
Lt. Limbic Lobe 
Cingulate 
Gyrus 
0.89 -2.3 29 24 4.62 342 
Lt. Occipital 
Lobe 
Lingual Gyrus -3.8 -81 1.1 18 3.84 309 
Lt. Occipital 
Lobe 






-40 -44 15 13 4.11 301 





Table 3-4-Apolipoprotein E-epsilon-4 Based Differences in BOLD Activation 
with Insulin Compared to Saline.  Increased activation in the non-carriers 
compared to carriers between the insulin and saline conditions was observed at the 




Lobe Landmark X Y Z 
Brodmann 
Area 








36 -61 28 39 4.65 1738 
Rt. Parietal 
Lobe 
Precuneus 12 -61 31 7 6.21 2417 
Rt. Occipital 
Lobe 
Lingual Gyrus 18 -67 4 19 5.11 667 
Rt. Occipital 
Lobe 










-51 -55 16 22 4.45 433 





-36 -52 46 40 4.49 587 
Lt. Parietal 
Lobe 
Precuneus -6 -61 46 7 4.86 576 
Lt. Occipital 
Lobe 
Precuneus -21 -67 22 31 3.97 440 
Lt. Limbic Lobe Posterior Cingulate -6 -58 10 30 5.30 678 
Lt. Limbic Lobe Posterior Cingulate -6 -37 16 29 4.31 665 
Lt. Limbic Lobe 
Parahippocampal 
Gyrus 
-30 -25 -17 35 4.75 351 

















Analysis of BOLD data was restricted to the hippocampus by session-specific masks 

















Figure 3-2-Insulin Modulation of Hippocampal Activation.   
 
 
There was a trend towards more HPAV in controls with saline compared to insulin.  
Total HPAV decreased between the saline and insulin conditions in the APOE-e4 
positive AD group, while non-carriers showed a non-significant increase.  Error bars 















BOLD activation during the memory encoding task was increased with insulin 
compared to saline in the overall AD group at several locations outside the medial 
temporal lobes, including the anterior aspect of the cingulate gyrus. Random effects 







Figure 3-4-APOE-e4-based Differences in Insulin Responses at the Left 















There was an interaction across APOE-e4 genotype in the AD group with regard to 
responses to insulin at the left parahippocampal gyrus. Random effects analysis, 































 Insulin administration appears to facilitate memory in early Alzheimer’s 
disease, but neither the anatomic correlates nor the mechanisms underlying this 
phenomenon are known.  Insulin might act specifically at hippocampal insulin 
receptors to modulate memory performance, but insulin might also act to improve 
memory via less specific means.  The goal of this experiment was to characterize 
insulin responses during a non-memory task with functional MRI.  It was 
hypothesized that motor activation would be increased with insulin compared to 
saline in all subjects.  The results of this experiment demonstrate that insulin might 
modulate non-memory related function in AD subjects, and that motor responses to 
insulin might differ according to apolipoprotein E-epsilon-4 genotype.  The results of 
this experiment therefore suggest that extra-hippocampal effects of insulin might 









Several reports of acute improvements in cognitive performance in AD after 
experimental insulin administration suggest that insulin might modulate memory 
processes, (S. Craft, et al., 2000; S. Craft, et al., 1999; Craft, et al., 1993; Craft, et al., 
1996; M. Reger, et al., 2006; G. S. Watson & Craft, 2004)  Insulin’s effect on 
cognitive performance also appears to be modulated by apolipoprotein E-epsilon-4 
genotype,  with improved recall in non-carriers after a single 40IU dose delivered via 
intranasal spray, while carriers demonstrated impaired recall. (M. Reger, et al., 2006) 
 
The neuroanatomic correlates mediating this phenomenon are not established, 
although the hippocampus is a likely candidate.  Insulin receptors are found 
throughout the brain, but are most concentrated in select regions including the 
hippocampus and entorhinal cortex. (Hoyer, 1993; Liang & Chaung, 2006; Messier 
& Teutenberg, 2005b; M. Reger, et al., 2006)  Insulin has been shown in cell cultures 
to modulate the activity of NMDA receptors (Christie, et al., 1999) as well as the 
surface expression of AMPA receptors.  (Ahmadian, et al., 2004) It seems possible 
therefore that insulin might act specifically at the hippocampus to modulate LTP and 
LTD via alterations of NMDA and AMPA currents, translating to changes in 




How apolipoprotein E-epsilon-4 genotype might interact with insulin in terms 
of cognitive enhancement is not clear.  Glucose utilization has been shown to differ 
across apolipoprotein E-epsilon-4 genotype in AD, with less insulin-mediated 
glucose disposal in AD non-carriers compared to both AD carriers and control 
subjects during experimental hyperinsulinemia. (S. Craft, et al., 1999)  It seems 
therefore that the influence of the apolipoprotein E-epsilon-4 allele might modulate 
neuronal physiology during non-memory tasks in addition to the previously 
described effects on memory. 
 
The experiments described in Chapter 3 demonstrate that insulin modulates 
hippocampal function and cognitive performance in early AD according to 
apolipoprotein E-epsilon-4 genotype.  Insulin however might influence neuronal 
function outside of the hippocampus and still contribute to changes in cognitive 
performance.  The goal of this study was to determine if insulin administration was 
associated with changes in brain activation during a simple fMRI motor task in early 
AD.  We hypothesized that fMRI activation in motor cortex would increase with 
insulin compared to saline in both control and AD subjects.  Based on the lack of 
data to suggest apolipoprotein E-epsilon-4 genotype modulates non-memory effects 
of insulin, we hypothesized that motor responses between the saline and insulin 







Subjects: All participants were right-handed non-diabetics over the age of 60, 
and provided written informed consent in accordance with the University of Kansas 
Medical Center Human Subjects Committee. Diagnostic criteria for AD included 
gradual and progressive memory impairment and deficit in at least one other 
cognitive domain. (L Berg, et al., 1988) A thorough exam, including an interview 
with a collateral source familiar with the subject, was performed to characterize the 
presence and severity of dementia with the Clinical Dementia Rating (CDR) scale, 
(Morris, 1993) focusing on intrasubject change, rather than deviation from group 
norms. (Morris, 1993, 1997; Rockwood, et al., 2000) Participants included AD 
subjects with CDR scores of 0.5 and 1, while those with CDR scores of 0 served as 
controls.  Exclusion criteria (Burns, et al., 2007) included diabetes (defined as self-
reported insulin or oral hypoglycemic agent use, or fasting blood glucose > 126 
mg/dl), disorders other than AD with the potential to impair cognition, stroke, 
clinically significant depressive symptoms, abnormalities in vitamin B12 levels, 
positive rapid plasma reagin, abnormal thyroid function, or concurrent use of 
psychoactive or investigational medications.  All participants underwent fMRI 
scanning twice, once after insulin administration, and once after saline placebo in a 





Insulin Administration: A single forty IU dose of insulin aspart (Benedict, et 
al., 2007) or an equivalent volume of saline placebo was administered via nasal spray 
(M. A. Reger & S. Craft, 2006; M. A. Reger, et al., 2006) approximately 30 minutes 
prior to the fMRI motor task. Blood samples were obtained from the left antecubital 
vein prior to insulin administration just before and again about 1 hour after insulin or 
placebo administration to characterize changes in peripheral glucose in response to 
insulin administration.  
 
 Functional MRI Motor Task: A simple fMRI motor task was employed in this 
study.  Each of the 5 active blocks consisted of a green circle on a black background 
presented 5 times for a duration of 2 seconds, with a 2 second interstimulus gap.  A 
red circle replaced the green circle for the rest blocks, which were otherwise 
identical to the active blocks in timing and duration.  Text clues (“Move” and 
“Rest”) were included for each stimulus to serve as a reminder of the task.  Subjects 
were instructed to firmly squeeze a soft rubber bulb with their right hand when the 
green circle was presented, and to rest when the red circle was displayed.  The entire 
motor stimulus was 3 minutes 28 seconds in duration. Stimuli were presented with 
commercial software (Presentation, NeuroBehavioral Systems) using an LCD back 





 Functional MRI: All imaging was performed with a Siemens 3T Allegra 
scanner using a quadrature head coil.  A T1-weighed (Magnetization-Prepared Rapid 
Gradient Echo [MPRAGE]; TR=2500 ms, TE=4.38 ms, TI=1100ms, flip angle=8 
degrees, field of view 256x256mm with 18% oversample, slice 
thickness/gap/number=1mm/0/208) anatomic image was acquired to provide a 
backdrop on which to overlay functional data. Blood-Oxygen Level Dependent 
(BOLD; FOV=240x100, slice thickness/gap/number=5.0mm/0mm/25, TR=2000, 
TE=50, FA=90, 102 data points) sensitive EPI data were acquired parallel to the AC-
PC line during performance of the motor task.   
  
 Functional MRI Data Analysis: BOLD MRI data were assessed with 
BrainVoyagerQX.  T1-weighted data were re-sampled into 1x1x1 mm isometric 
voxels in a sagittal orientation and warped into a common stereotactic space. 
(Talairach & Tournoux, 1988) The first 8 seconds of fMRI data were discarded to 
allow for T1 stabilization.  Processing of the fMRI data began with sync-interpolated 
slice timing correction, followed by trilinear 3D motion correction, high-pass 
temporal filtering, (128 sec.) smoothing with a 4mm FWHM Gaussian filter, and 
warping into sterotactic space. (Talairach & Tournoux, 1988) Voxel-wise linear 
regression analysis of the fMRI data, employing a canonical hemodynamic response 
function and serial correlation correction, was used to compare the BOLD response 




characterize whole brain responses in the insulin condition to that of saline in both 
the control and overall AD groups, as well as across apolipoprotein E-epsilon-4 
genotype in the AD subjects.   Voxels within the primary motor cortex, ipsilateral 
motor cortex or supplemental motor area were considered active if their BOLD time 
course exhibited a positive or negative correlation with the expected response at 
p<0.001, uncorrected for multiple comparisons.  Interactions in BOLD response 
across apolipoprotein E epsilon-4 genotype were considered significant at p<0.001 
uncorrected for multiple comparisons as well.  Anatomic location and Brodmann 
classification of significant voxels were characterized with the Talairach Client 
(www.talairach.org). 
 
 Statistical Analysis: Group differences in age, weight, education, fasting 
glucose and insulin levels were assessed with the Kruskall-Wallis test, while the chi-
square test was used to characterize proportions of non-continuous data between 
groups.  Differences in plasma glucose and insulin levels between the placebo and 
insulin conditions were assessed with Wilcoxon Signed-Ranks test. All statistical 









Sample Characteristics: Ten cognitively intact control subjects and 18 early 
AD subjects were enrolled and completed the study, but one of the AD subjects 
exhibited excessive motion during both fMRI sessions and this data was excluded 
from analysis.  Ten of the remaining AD subjects carried at least 1 apolipoprotein E-
epsilon-4 allele, while 7 AD subjects were apolipoprotein E-epsilon-4 negative. 
Baseline peripheral glucose and insulin levels were similar in all groups. Sample 
characteristics are presented in Table 4-1.  The sex distribution between the control 
(70% female) and AD (24%) groups was unequal. (chi-square 5.6, df=1, p=0.02)  
The drug order randomization was equal between the two groups. (chi-square 1.3, 
df=1, p=0.23) 
 
Plasma Glucose: Plasma glucose was marginally statistically lower (p=0.05) 
after insulin administration, lowering by about 2 mg/dl from a value of 91.3 mg/dl 
before insulin to 89.1 mg/dl after. None of the participants however experienced any 






Functional MRI Results: The motor task produced the expected BOLD 
activation in the contralateral (left) primary motor cortex, as well as at the ipsilateral 
(right) motor cortex and supplemental motor area in both the control and AD groups.  
Random effects analysis comparing motor responses between the saline and insulin 
conditions revealed no differences in the control group.  Evaluation of imaging data 
in the overall AD group showed several regions which exhibited greater BOLD 
activation with insulin compared to saline (Table 4-2), but none were found within 
the primary motor cortex, ipsilateral motor cortex or supplemental motor area.  
Comparison of insulin-related changes in BOLD motor responses across 
apolipoprotein E-epsilon 4 genotype in AD did reveal increased activation at the 
ipsilateral precentral gyrus (x, y, z = 36, -19, 40) in the non-carriers compared to the 















The results of this preliminary study suggest apolipoprotein E-epsilon-4 
based differences in BOLD responses to insulin during a simple motor task in AD.  
Apolipoprotein E-epsilon-4 negative AD persons are at increased type 2 diabetes risk 
compared to carriers, suggesting differences in peripheral insulin sensitivity across 
apolipoprotein E-epsilon-4 genotype, but how this might translate to the central 
nervous system is not clear.  The differences occurred at the ipsilateral motor cortex, 
which is though to contribute about ten percent of the total cortical motor output 
during such tasks, although why no differences were observed at the site of greatest 
activity, the contralateral motor cortex, is not clear.   
 
Several explanations might offer insight in our observations.  As mentioned 
earlier, insulin increases CSF norepinephrine levels, (G. Watson, et al., 2006) 
possibly by modulating NE transporter mRNA transcription at the locus ceruleus 
(Figlewicz, Szot, Israel, Payne, & Dorsa, 1993) via a MAP kinase pathway. (Kusari, 
Byon, Bandyopadhyay, Kenner, & Kusari, 1997) Noradrenergic signaling increases 
cortical excitability by inhibiting slow-acting potassium channels, resulting in 
decreased after-hyperpolarization. (Andersen, Morris, Amaral, Bliss, & O'Keefe, 
2007)  Therefore, insulin administration might increase task-related BOLD signal by 




Insulin’s potential effects on cortical excitability however might be more 
complex.  Motor cortex hyperexcitability is a feature of Alzheimer’s disease, and 
might be mediated by a shift in balance of glutamate signaling from NMDA to non-
NMDA receptor types, such as the kainate receptor.  (Di Larzzaro, et al., 2003; Di 
Larzzaro, et al., 2004)  Insulin and IGF-1 have been shown to prevent kainite 
neurotoxicity via a PI3-K dependent pathway. (Leski, Valentine, Baer, & Coyle, 
2000) One of insulin’s actions might therefore include attenuation of cortical 
excitability by modulation of kainite signaling. However, reduced IRS-1-related PI3-
K levels have been described in AD (Steen, et al., 2005), suggesting that insulin’s 
inhibitory effect on cortical excitability via kainite receptors might be attenuated in 
AD. The balance therefore between insulin’s facilatory and inhibitory mechanisms 
regulating cortical excitability might be upset in AD, leading to increased excitability 
in response to insulin.   
 
Alternatively, insulin’s effect on motor activation might reflect insulin-
induced facilitation of oxidative metabolism. Insulin promotes trapping of glucose 
within neurons by phosphorylation of hexokinase and phosphofructokinase, initiating 
oxidative metabolism and leading ultimately to ATP production.  Attenuated glucose 
metabolism has been reported in AD, (Fukuyama, et al., 1994) and insulin-related 
increases in oxidative metabolism and ATP production might therefore translate into 




How these mechanisms might interact with the apolipoprotein E-epsilon-4 
allele is however not clear.  It is noteworthy however that the apolipoprotein E-
epsilon-4 genotype appears to interact with β2 polymorphisms to confer increased 
AD risk.  These polymorphisms also exhibit different signaling qualities, (Yu, et al., 
2008) suggesting that noradrenergic mechanisms might differ across apolipoprotein 
E-epsilon-4 genotype.  It has also been that the antidepressant mirtazapine, which 
inhibits the reuptake of both norepinephrine and serotonin, appears to work faster in 
apolipoprotein E-epsilon-4 positive subjects compared to non-carriers.  Thus the 
apolipoprotein E-espilon-4 based differences described might suggest that insulin’s 
effects on neuronal physiology are mediated by noradrenergic mechanisms. 
 
Insulin is also known to act as a vasodilator, (E. A. Anderson & Mark, 1993) 
but increased regional blood flow would be expected to decrease rather than increase 
BOLD signal as we describe.  Hyperinsulinemia has been shown to be associated 
with decrease BOLD signal during visual stimulation, (Seaquist, et al., 2007) 
attributed to increased regional blood flow.  It seems unlikely therefore that the 
increased BOLD signal we observed is driven by insulin’s vasodilatory properties, 





In summary, compared to saline, a single 40IU dose of insulin appears to 
modulate ipsilateral motor cortex BOLD signal during a simple motor task according 
to apolipoprotein E-epsilon-4 genotype in AD.  In the context of understanding 
insulin’s effect on cognitive performance in AD, this suggests that insulin might act 
to improve memory by modulating widespread cortical functions, rather than by 
acting specifically at temporal lobe structures, such as the hippocampus, to produce 
cognitive enhancement.  Reports of apolipoprotein E-epsilon-4 based differences in 
noradrenergic signaling suggest that insulin might act via noradrenergic mechanisms.  














Table 4-1. Sample Characteristics 
 
 Control (n=10) Early AD (n=18) p-value 
Age (years)  73.6 (6.3) 72.5 (8.0) 0.65 
Fasting Plasma Glucose 
(mg/dl) 
97.9 (12.8) 94.0 (9.1) 0.28 
Weight (lbs) 149.8 (29.8) 173.8 (28.7) 0.05 










Table 4-2-Clusters Demonstrating Greater Motor Activation With Insulin Compared 
to Saline in AD.  
 
 
Lobe Landmark X Y Z 
Brodmann 
Area 







55 -26 21 40 4.29 311 
Rt. Occipital 
Lobe 
Cuneus 20 -80 4.9 17 5.45 467 
Lt. Limbic Lobe 
Anterior 
Cingulate 
8.8 33 17 24 5.26 487 
Lt. Limbic Lobe 
Cingulate 
Gyrus 
















-40 -44 15 13 4.11 301 




Figure 4-1-Insulin-Related Differences in Motor Activation Across APOE-e4 


















Apolipoprotein E-epsilon-4 negative AD subjects exhibited greater insulin-related 
activation change compared to non-carriers at the right pre-central gyrus during a 


































 Insulin administration appears to facilitate memory in early Alzheimer’s 
disease, but the mechanisms underlying this phenomenon are not known.  Insulin is 
known to act as a vasodilator peripherally, and such an effect if it occurs centrally 
might contribute to insulin-related cognitive enhancement.  Insulin-related changes 
in mean cerebral blood flow might also confound blood oxygen level based 
functional MRI experiments investigating insulin’s effect on cognition.  Mean 
cerebral blood flow was assessed with arterial spin-labeled MRI after intranasal 
saline and insulin administration, hypothesizing that mean cerebral blood flow would 
increase with insulin in all subjects.  Our experiment found no insulin-related 
changes in mean cerebral blood flow after a single 40IU dose of insulin delivered via 
nasal, suggesting that insulin’s effects on cognitive performance are not mediated by 










Several reports of acute improvements in cognitive performance in AD after 
experimental insulin administration suggest that insulin might modulate memory 
processes, although the mechanisms related to this phenomenon are not clear. While 
insulin receptors are found throughout the brain, most are concentrated in select 
regions including the hippocampus and entorhinal cortex (Hoyer, 1993; Liang & 
Chaung, 2006; Messier & Teutenberg, 2005a; Seaquist, et al., 2007) where insulin 
might modulate long term potentiation (LTP) and long-term depression (LTD) 
mechanisms. ((Ahmadian, et al., 2004; Christie, et al., 1999) It therefore seems 
possible that insulin might directly modulate hippocampal function to facilitate 
memory. 
 
Insulin however also possesses vasodilatory properties peripherally, acting at 
endothelium to increase nitric oxide (NO) production. (E. A. Anderson & Mark, 
1993)  Such vasodilatory effects could contribute to insulin effect on memory by 
increasing delivery of glucose and oxygen to metabolically active areas either the 





Reductions in parietal-temporal and frontal blood flow in AD have been 
reported, and these appear to be related to clinical presentation in early AD. 
(Postiglione, Lassen, & Holman, 1993) Right-sided flow deficits for example are 
associated with visuospatial apraxia, suggesting that alterations in cerebral blood 
flow may be an important aspect of disease expression.  Cilostazol, a PDE3 
phosphodiesterase inhibitor that acts as an antiplatelet agent as well as a vasodilator, 
used in conjunction with cholinesterase inhibitors has been shown to lead to 
improved MMSE scores in AD after 5-6 months, (Arai & Takahashi, 2009) 
suggesting that increasing cerebral blood flow might improve cognitive performance 
in AD.  It is not known how or if cerebral flow deficits in AD respond to insulin, but 
a possible mechanism underlying reports of insulin-related cognitive enhancement 
might involve changes in cerebral blood flow. 
 
 
Insulin’s vasodilator action also has the potential to confound BOLD-based 
functional MRI (fMRI) studies.  The BOLD effect is a complex phenomenon based 
in the physiologic response of blood vessels to adjacent brain activity.  In the 
simplest case, the identification of brain “activity” with BOLD fMRI depends in 
large part on the difference in blood flow between two states, such as “rest” and 
“active” in a region over time.  Larger differences in blood flow translate to greater 




“active” states in a typical experiment is small, on the order of 1-2%. Vasodilators 
such as acetoazolamide tend to cause a persistent increase in basal blood flow 
(Vagal, Leach, Fernandez-Ulloa, & Zuccarello, 2009) and minimize the differences 
in regional blood flow between contrasting conditions (i.e. “rest” and “active) in 
response to task-related modulation of neuronal activity. Experimentally-induced 
hyperinsulinemia has been shown to decrease BOLD signal during visual 
stimulation, with no change in neuronal activity as measured by visually evoked 
potentials. (Seaquist, et al., 2007) This disparity between imaging modalities was 
thought to be due to insulin-related vasodilation.  Characterizing any insulin-related 
changes in cerebral blood flow therefore might be important when interpreting 
BOLD imaging of insulin effects. 
 
 
The method of delivery however might influence the vasodilatory effects of 
insulin. Insulin administered via IV has ready access to endothelium, where it can 
promote NO production, but how insulin given via nasal spray might behave in this 
regard is not known.  Small peptides delivered via nasal spray appear to bypass the 
peripheral circulation and directly access the CSF by traveling along trigeminal 
nerves. Insulin administered in this manner would presumably have to traverse 




vasodilation.  It seems therefore that insulin delivered via nasal spray might not be as 
effective in altering blood flow as insulin delivered via IV might be. 
 
Because insulin-induced changes in blood flow might contribute to cognitive 
performance and confound BOLD imaging, mean cerebral blood flow after both 
saline and insulin administration was measured with arterial spin-labeled MRI (ASL-
MRI) in 8 cognitively intact older adults and 13 early AD subjects.  It was 
hypothesized that mean cerebral blood flow would be greater after insulin 
administration compared to that in the saline condition. Based on earlier PET reports, 
it was anticipated that the AD group would demonstrate reduced cerebral blood flow 









Subject Selection: All participants were right-handed non-diabetics over the 
age of 60, and provided written informed consent in accordance with the University 
of Kansas Medical Center Human Subjects Committee. Diagnostic criteria for AD 
included gradual and progressive memory impairment and decline in at least one 
other cognitive domain. (L Berg, et al., 1988) A thorough exam, including an 
interview with a collateral source familiar with the subject, was performed to 
characterize the presence and severity of dementia with the Clinical Dementia Rating 
(CDR) scale, (Morris, 1993) focusing on intrasubject change rather than deviation 
from group norms. (Morris, 1993, 1997; Rockwood, et al., 2000) Participants 
included AD subjects with CDR scores of 0.5 and 1, while those with CDR scores of 
0 served as controls.  Exclusion criteria (Burns, et al., 2007) included diabetes 
(defined as self-reported insulin or oral hypoglycemic agent use, or fasting blood 
glucose > 126 mg/dl), disorders other than AD with the potential to impair cognition, 
stroke, clinically significant depressive symptoms, abnormalities in vitamin B12 
levels, positive rapid plasma reagin, abnormal thyroid function, or concurrent use of 
psychoactive or investigational medications. Apolipoprotein E genotype in the AD 
subjects was determined by allelic discrimination. Participants were not excluded 
from this pilot if they were currently taking AD medications such as cholinesterase 





 All participants underwent MRI scanning on two occasions at least 48 hours 
apart in a double-blind, crossover, counterbalanced manner. All scanning was 
performed in the morning after an overnight fast.  Participants were instructed to take 
any morning medications as usual, and to maintain their usual caffeine intake on 
study days.  For each visit, either 40IU insulin aspart, (Benedict, et al., 2007) or an 
equal volume of saline placebo, was administered via nasal spray.  (M. A. Reger & 
S. Craft, 2006) An IV line was placed prior to insulin administration for pre and 
post-drug/placebo glucose and insulin testing, and for ready vascular access for 
dextrose infusion if necessary due to hypoglycemia. 
 
Image Acquisition: A Siemens 3T Allegra scanner using a quadrature head coil 
was used for all imaging.  Following routine localizer scans for anatomic orientation, 
2D time-of-flight MR angiography was used to visualize carotid artery anatomy 
within the upper cervical region.  The distance between the isocenter of the magnet 
and the junction of the cavernous and cerebral portions of the internal carotid arteries 
was recorded and used to adjust the label offset distance parameter for each subject.  
This step was to minimize differences in labeling efficiency related to variability in 





Cerebral Blood Flow; Arterial Spin Labeling (ASL-MRI): Forty labeled and 40 
unlabeled image pairs were acquired perpendicular to the magnet axis over a period 
of 5 minutes, 34 seconds. (FOV=240mmx100mm, slice 
thickness/gap/number=8.0mm/2.0mm/10, TR=4000, TE=16.0, FA=90) The DICOM 
data were converted to ANALYZE format, and the 40 unlabeled images were 
averaged into a single mean unlabeled image file using the imagecalc function of 
SPM5.  Similarly, the 40 labeled images are averaged into a single mean labeled 
image.   
 
 The mean signal intensity from four identical 10mm spherical regions, (left 
frontal, right frontal, left occipital, right occipital) including both gray and white 
matter (Figure 5-1), in each of the mean labeled and mean un-labeled image was 
recorded and used to calculate regional blood flow at each of the 4 locations 
according to previously published reports. (Wang, et al., 2003) The 4 regional 
cerebral blood flow values were averaged to provide an estimate of mean cerebral 
blood flow for the session.   
 
 Statistical Analysis: Group differences in age, weight, education, fasting 
glucose and baseline mean cerebral blood flow were assessed with Kruskall-Wallis 




data between groups.  Differences in plasma glucose and mean cerebral blood flow 
between the placebo and insulin conditions were assessed with the Wilcoxon Signed 

















 The control and AD groups were similar in terms of age, fasting glucose and 
baseline mean cerebral blood flow, although there was a trend towards greater 
weight in the AD group. (Table 5-1) The groups were different however in sex 
distribution, with 25% females in the control group, and 77% females in the AD 
group. (chi-square 5.45, df=1. p=0.03)  The order of drug administration was similar 
between the groups. (chi-square 1.15, df=1, p=0.27) 
 
 Mean plasma glucose in the overall group was similar before (90.7 mg/dl, SD 
13.1) and after (88.9 mg/dl, SD 12.6) insulin administration (p=0.09) suggesting 
there may have been a slight and physiologically negligible trend towards lower 
plasma glucose levels with insulin.   
 
 The values obtained for mean cerebral blood flow were higher than the 
expected value of 50 ml/100g/min.  Mean CBF in the overall group during the saline 
condition for example was 81.83 ml/100g/min (one-sample t-test for saline mean 
cerebral blood flow vs. 50 ml/100g/min, p<0.001)  Mean cerebral blood flow in the 
overall group was the same in both the saline (81.83 ml/100g/min, SD 26.8 
mg/100g/min) and insulin (82.89 mg/100g/min, SD 25.9 mg/100g/min) conditions. 




different between the saline (77.0 ml/100g/min, SD 16.4 mg/100g/min) and insulin 
(84.1 ml/100g/min, SD 30.8 mg/100g/min) conditions. (p=0.56)  Mean cerebral 
blood flow in the AD group was also not significantly different in the saline (84.8 
ml/100g/min, SD 31.9 mg/100g/min) and insulin (82.1 ml/100g/min, SD 23.8 
mg/100g/min) conditions. (p=0.75)  Furthermore, there were no significant 
apolipoprotein-E-epsilon-4 based differences in insulin-related change in mean CBF 















Table 5-1.  Sample Characteristics 
 Control (n=8) Early AD (n=13) p-value 
Age (years) 73.3 (5.7) 71.2 (8.2) 0.70 
Weight (lbs.) 152.9 (32.7) 171.8 (27.1) 0.07 
Fasting Glucose (mg/dl) 99.2 (14.2) 91.1 (8.8) 0.22 
Mean CBF (ml/110g/min, saline 
condition) 






























Signal intensity from 4 regions (red) was measured for both mean labeled and un-


















Figure 5-2-Mean Cerebral Blood in Control and Early AD Subjects.   
 
 
No change in mean cerebral blood flow was evident between the saline and insulin 
conditions in either the overall group or the separate diagnosis groups (shown).  
















 Our results show that a single 40IU dose of insulin aspart does not appear to 
alter mean cerebral blood flow as measured with ASL-MRI.   Our results however 
must be interpreted with several caveats in mind.  First, the cerebral blood flow 
measurements were delayed about 30 minutes after drug administration while 
subjects were positioned within the scanner and the initial localizer scans obtained.  
The CSF pharmacokinetics of insulin administered via nasal spray are not well 
understood, and it is possible that cerebral blood flow measurements made earlier (or 
later) might have yielded different results.  Second, the mean cerebral blood flow 
values are greater than the generally agreed upon mean cerebral blood flow value of 
50ml/100g/min, and furthermore do not appear to be in agreement with other studies 
that demonstrate reduced cerebral blood flow in AD.  This would suggest that the 
mean cerebral blood flow measurement as performed might not be accurate or 
sensitive enough to produce meaningful measures of blood flow.  Our ASL 
measurement appears to exhibit quite a bit of variability as well.  The 95% 
confidence interval of the mean difference in mean cerebral blood flow between the 
saline and insulin conditions is -9.47-11.59 ml/100g/min, suggesting that ASL-MRI 
as performed might not be an adequately sensitive measure for small samples such as 
this.  However, we measured resting mean cerebral blood flow, rather than task-
related changes in regional cerebral blood flow.  It might be that insulin modulates 




detecting task-related changes in regional blood flow, rather than mean cerebral 
blood flow during rest. 
 
 The lab results suggest that there might have been a decrease in plasma glucose 
in the insulin condition relative to saline, however plasma glucose was still well 
above the lower limits of normal, and none of the subjects experienced symptoms of 
hypoglycemia. A larger sample might clarify this discrepancy with earlier reports 
that intranasal insulin does not influence peripheral glucose.   
 
 In summary, mean cerebral blood flow in our sample did not appear to change 
with insulin, however it is not clear if this indicates that intranasal insulin does not 
influence mean cerebral blood flow, or that the ASL-MRI method we used is not 









Table 5-1. Sample Characteristics 
  Control (n=8) AD (n=13) p-value  
Age (years) 73.3 (5.7) 71.2 (8.2) 0.54 
Percent Female 25 77 0.03 
Weight (lbs.) 152.9 (32.7) 171.8 (27.1) 0.19 
Fasting Glucose (mg/dl) 99.2 (14.2) 92.1 (8.8) 0.18 
Baseline mean CBF 
(ml/100g/min) 
77.0 (16.4) 84.8 (31.9) 0.47 



































Summary of Findings 
 
Chapter 2-Hippocampal and Limbic Volume Are Related to Insulin Levels in Early 
Alzheimer’s Disease 
 
Peripheral insulin appears to positively correlate with whole brain volume in 
early AD. (Burns, et al., 2007) The goal of this experiment was to examine this 
relationship on a regional basis.  It has been postulated that insulin signaling might 
act to modulate pathologic burden in AD by inhibiting the formation of both Abeta-
42 and neurofibrillary tangles.  Brain volume loss as assessed with MRI frequently 
used to quantify pathologic burden in AD. (Borthakur, et al., 2008; Callen, et al., 
2001; Clark, et al., 2008; Hall, et al., 2008) Therefore, if insulin acts to attenuate AD 
pathologic burden, insulin levels should positively correlate with volume in regions 
known to possess insulin receptors, in particular the hippocampus.  We found a 
positive correlation between peripheral insulin level and hippocampal volume, as 
well as that of paralimbic structures, in the overall AD group without regard for 
apolipoprotein E-epsilon-4 genotype.  This might represent either a neurotrophic or 
neuroprotective influence of insulin on insulin-sensitive anatomy, and provides 
additional evidence that insulin may be an important factor in brain health in AD.  




AD, although longitudinal studies that monitor changes in hippocampal volume over 
time a necessary to define insulin’s influence on brain structure.  
 
Chapter 3-Insulin Modulates Hippocampal Activation During Memory Encoding in 
Early Alzheimer’s Disease According to Apolipoprotein E-epsilon-4 Genotype 
 
The aim of this experiment was to characterize hippocampal responses to 
insulin in early AD, and secondarily to assess differences in insulin responses across 
apolipoprotein E-epsilon-4 genotype in AD.  Insulin has been shown to improve 
memory acutely in early AD, and this phenomenon appears to be most pronounced 
in apolipoprotein E-epsilon-4 negative AD subjects.  The hippocampus is a structure 
key to memory function, and is known to express insulin receptors that might 
modulate long-term depression and potentiation mechanisms, suggesting that insulin 
might act at the hippocampus to influence memory performance. The results 
demonstrate that hippocampal activation in AD between the saline and insulin 
conditions differs according to apolipoprotein E-epsilon-4 genotype, with carriers 
exhibiting decreased hippocampal activation in response to insulin.  The changes in 
hippocampal activation during memory encoding across apolipoprotein E-epsilon-4 
genotype were paralleled by changes in image recall performance, suggesting a link 




related changes in performance on the standardized cognitive tests, which might 
reflect a relatively short duration of action for insulin.  
 
The apolipoprotein E-epsilon-4 based differences in hippocampal insulin 
responses suggest there might be fundamental differences in insulin signaling 
between the two groups.  Alzheimer’s disease subjects who are not carriers of this 
gene have been shown to have increased risk for type 2 diabetes and obesity, 
(Profenno & Faraone, 2008) suggesting peripheral insulin signaling alterations in this 
subgroup of AD subjects, but how this might be related to brain insulin signaling is 
not clear.  Although the hippocampal activation changes between the saline and 
insulin conditions in the apolipoprotein E-epsilon-4 negative AD group described 
herein did not reach statistical significance, mean activation did increase in this 
group with insulin.  This increased activity and image recall performance associated 
with insulin administration might represent  preliminary evidence of impaired insulin 
signaling or perhaps insulin resistance specifically in apolipoprotein E-epsilon-4 
negative AD.  Furthermore, the observations of attenuated hippocampal responses 
paralleled by a trend towards decreased cognitive performance with insulin in the 
apolipoprotein E-epsilon-4 carriers suggest that augmentation of insulin signaling 
might be detrimental to this AD subgroup, however the possible reasons for this 
observation are not clear. This general profile of increased cognitive performance in 




apolipoprotein E-epsilon-4 positive AD with insulin is in line with other reports, and 
it therefore appears possible that insulin-related changes in hippocampal function 
might underlie insulin-mediated memory facilitation in early AD.   
 
The lack of insulin-related change in performance on the standardized 
cognitive testing however suggests an alternate interpretation.  It might be that the 
apolipoprotein E-epsilon-4 positive AD subjects, who showed decreased 
hippocampal activation with insulin compared to saline along with similar cognitive 
performance between the saline and insulin conditions, were able to maintain 
constant cognitive performance with less hippocampal engagement with insulin 
compared to saline. The findings in the apolipoprotein E-epsilon-4 negative AD 
group, which exhibited no change in performance on the standardized cognitive 
testing between the saline and insulin conditions, and demonstrated an increase 
(although statistically insignificant) in hippocampal activation, might suggest that 
these subject had to engage more hippocampus with insulin to maintain the 
performance attained with saline.  Thus, in light of the lack of insulin-related change 
in performance on the standardized cognitive testing, it may not be entirely clear if 






It is not clear if more hippocampal activation is necessarily better.  Increased 
BOLD activation for example has been observed in mild cognitive impairment, and 
might indicate compensatory recruitment of adjacent tissue in a setting of chronic but 
sub-clinical degeneration.  (Borghesani, et al., 2007; Han, et al., 2007) A clear 
cognitive response to insulin would help clarify if more or less hippocampal 
activation in response to insulin is actually beneficial in terms of memory.  While 
image recall performance increased with insulin in the apolipoprotein E-epsilon-4 
negative AD group in line with previous reports, there were essentially no other 
definite memory effects by which to judge the hippocampal responses.  One possible 
explanation for this is that the time between insulin administration and testing during 
this study was much greater than reported by others, (S Craft, S Asthana, G 
Schellenberg, et al., 1999; Craft, et al., 1996; M. A. Reger & S. Craft, 2006; G. S. 
Watson & Craft, 2004) where testing began within 15 minutes after insulin 
administration. The times of insulin administration and the start of the first BOLD 
fMRI sequence were recorded, (mean delay 41.4 minutes, SD 9.3 minutes) and it 
was found that there was a negative correlation between this time delay and global 
cognitive performance, but only in the AD subjects, (Spearman’s Rho = -0.791, p < 
0.001) while no correlation was evident in the AD subjects with saline, or in the 





Most of the variability in 
this delay was related to the 
necessity of placing the 
subjects in the scanner and 
adjusting the back 
projection system, while the 
pace of the subsequent 
events preceding the 
cognitive testing was fairly 
steady, dictated mostly by the 
programming of the MRI 
scanner.  There were no differences in the delay between the saline and insulin 
conditions, (Wilcoxon test, p=0.52) or in this delay between the control and AD 
subjects.  (Mann-Whitney U test, p=0.46) The negative correlation between drug-
testing delay and global cognitive performance in AD with insulin might suggest that 
any effects of insulin were waning by the time of formal cognitive testing.  That an 
insulin-related change in image recall performance was noted might be related to the 
fact that the timing of this test during the sequence of procedures placed it as the first 
cognitive measure after insulin administration, although typically no more than 10-
15 minutes before the standardized cognitive testing.  The CSF pharmacokinetics of 
insulin delivered via nasal spray are not well documented, but the results of this 
Scores on the standardized cognitive testing 
measures negatively correlated with the delay 
between insulin administration and testing.   
Figure 6-1-Relationship Between the 
Insulin Administration-Cognitive Testing 




study might suggest that any cognitive effects are short lived, perhaps on the order of 
an hour or so.   
 
Chapter 4-Insulin and fMRI Motor Activity in Early Alzheimer’s Disease 
 
This experiment was conducted to assess insulin’s effect on non-memory 
related tasks as a control for the hippocampal activation experiment.  If insulin acts 
specifically at hippocampal insulin receptors to modulate long-term depression and 
potentiation mechanisms that drive changes in cognitive performance, then 
activation during a simple motor task, unrelated to memory encoding, should show 
no change between the saline and insulin conditions.   
 
The results of this study however demonstrated that insulin might alter task-
related activation at the ipsilateral (i.e. right) motor cortex according to 
apolipoprotein E-epsilon-4 genotype in AD.  The motor findings therefore appear to 
parallel those of the memory encoding experiment, and suggest that insulin might act 
in a general and non-specific manner, rather than specifically at the hippocampus to 





Chapter 5-Mean Cerebral Blood Flow is Not Altered After Intranasal Insulin 
Administration 
 
Insulin is known to act as a vasodilator peripherally via an endothelial nitric 
oxide (NO) dependent mechanism. (Dallinger, et al., 2003; Randriamboavonjy, 
Schrader, Busse, & Fleming, 2004) Such vasodilatory effects could contribute to 
insulin effect on memory by increasing delivery of glucose and oxygen to either the 
entire brain, or regionally to metabolically active areas.  Furthermore, 
pharmacologically induced changes in blood flow can confound BOLD-based 
imaging.  For these reasons, an attempt was made to non-invasively measure mean 
CBF.  Arterial spin-labeled MRI (ASL-MRI) data were acquired on the last 21 
participants. (8 controls and 13 early AD subjects)  It was anticipated that insulin 
would increase mean CBF compared to saline.  The results of the ASL-MRI 
experiments showed no statistically significant change in mean CBF between the 
saline and insulin conditions.  There appeared to be however a large degree of 
variability in the individual measures.  Post-hoc calculations showed the 95% 
confidence interval of the mean change between conditions to be -9.47-11.59 
ml/100g/min, again suggesting that there was no insulin-related change in mean 
CBF.  It might be that the ASL method used is not sensitive to small changes in 
mean CBF, or that in fact insulin did not alter mean cerebral blood flow.  The 




82.9, SD 25.9) are however significantly different from the generally accepted mean 
of 50 ml/100g/min for normal gray matter, (mean CBF with saline, one-sample t-test, 
p<0.001) suggesting that the method used lacked accuracy.  Alternatively, insulin 
might modulate task-related changes in regional blood flow, rather than mean 
cerebral blood flow during rest.  Thus, assessment of changes in task-dependent 
regional cerebral blood flow with insulin might be more informative than resting 















Insulin and Brain Health and Function in Alzheimer’s Disease 
 
The work presented herein was undertaken to characterize the role of insulin 
in hippocampal structure and function in early Alzheimer’s disease. The results of 
preliminary experiments demonstrated first an AD-specific positive correlation 
between peripheral insulin levels and hippocampal volume, consistent with insulin’s 
proposed neurotrophic and neuroprotective properties.  In terms of memory function, 
there were distinct differences in the hippocampal and medial temporal lobe fMRI 
activation with insulin across apolipoprotein E-epsilon-4 genotype in AD.  The 
changes in hippocampal activation were paralleled by changes in cognitive 
performance suggesting that modulation of hippocampal and related medial temporal 
lobe activity by insulin could explain reports of insulin-related memory facilitation in 
AD.  The motor fMRI experiment also demonstrated an apolipoprotein E-epsilon-4 
based interaction in AD subjects similar to that seen for the memory task.  In the 
context of understanding the general effects of insulin on brain activity, the results of 
the motor fMRI experiment suggest that insulin might influence extra-hippocampal 
regions to contribute to cognitive enhancement. Last, mean cerebral blood flow 
measured with arterial spin-labeled MRI was the same in both the saline and insulin 
conditions, suggesting that insulin’s effects on brain activity are not mediated by 
changes in mean cerebral blood flow.  These experiments suggest an AD-specific 




body of research suggesting that insulin may play an important role in modulating 
AD pathology.  Insulin also appears to influence neuronal physiology in AD 
according to apolipoprotein E-epsilon-4 genotype.  During both the memory and 
motor tasks, apolipoprotein E-epsilon-4 negative AD subjects exhibited greater task-
related BOLD activation with insulin compared to saline than their apolipoprotein E-
epsilon-4 positive counterparts.  The fact that insulin’s trophic effects on 
hippocampal volume do not appear to differ according to apolipoprotein E-epsilon-4 
genotype however suggest that the long-term and acute effects of insulin might be 
mediated  by different mechanisms.  It is hoped that the results of these studies will 
contribute to the growing body of research focused on brain insulin signaling in AD, 
and ultimately translate into novel AD prevention and treatment strategies. 
 
Insulin might act to promote neuronal health and survival in several manners.  
The most obvious is its role in the promotion of oxidative metabolism. Insulin 
signaling is linked to hexokinase and phosphofructokinase activity, enzymes that 
initiate glycolysis and therefore ultimately lead to ATP production. Considering the 
nearly universal role of ATP in practically all cellular functions, impaired insulin 
signaling might be expected to impact a variety of energy-dependent activities.  
Insulin dysfunction along with altered glucose metabolism appears to occur in AD. 
(S. Craft, et al., 2000; Craft, et al., 1993; Frolich, et al., 1999; Hoyer, 2004a, 2004b) 




cerebral metabolic disturbance in AD.  Insulin might also act as a specific growth 
factor, influencing neuronal health and survival.  Insulin-like growth factor-1 (IGF-
1) shares structural and signaling similarities with insulin, and is known to increase 
neurogenesis in the adult rat hippocampus, (M. F. Anderson, Aberg, Nilsson, & 
Eriksson, 2002)  and several studies have shown decreased insulin and IGF-1 action 
specifically in AD.(de la Monte & Wands, 2005; Rivera, et al., 2005; Steen, et al., 
2005)  It might be that insulin is related to neurogenesis (Jackson-Guilford, Leander, 
& Nisenbaum, 2000) during normal aging, and that impaired insulin action seen in 
the AD brain might therefore contribute to neuronal loss.   
 
Insulin also appears to play a central role in AD neuropathology.  Abeta-42 is 
a product of amyloid precursor protein (APP) metabolism and a major constituent of 
the amyloid plaques seen in AD.  The amyloidogenic degradation of APP begins 
with initial cleavage by beta-secretase, followed by further action on the resulting C-
terminal fragment by gamma secretase.  Insulin acts to decrease Abeta production by 
inhibiting gamma-secretase activity via glycogen synthase kinase-3-beta (GKS-3) 
inhibition.  Thus impaired insulin signaling might remove inhibitory control over 
gamma-secretase activity and lead to increased Abeta production. (Phiel, et al., 2003) 
An GSK-3 isoform GSK-3 acts to phosphorylate tau, and is also under inhibitory 
influence of insulin signaling mechanisms.  Impaired insulin action therefore might 




formation characteristic of AD. (Muyllaert, et al., 2006)  These two isoforms of 
GSK-3 would therefore appear to be central to insulin’s effects on AD 
neuropathology, and the role of GSK-3 in this regard is substantiated by reports of 
reduced Abeta production after lithium (an inhibitor of GSK-3 activity) 
administration. (Phiel, et al., 2003)  Further evidence of insulin’s effect of AD 
neuropathology is provided by reports of reversible tau phosphorylation in 
streptozotocin (STZ) treated rats. (Schechter, et al., 2005) In normal humans, Insulin 
administration is associated with increased CSF Abeta-42, consistent with decreased 
deposition and increased clearance of this amyloidogenic species. (G. Watson, et al., 
2003) Insulin administration also appears to increase the plasma Abeta-40/42 ratio, 
((M. Reger, Watson, Green, Wilkinson, et al., 2008) again suggesting that insulin 
signaling can modulate amyloid metabolism in a favorable manner.  Thus, it appears 
that insulin modulates the metabolism of both Abeta and tau in a manner that inhibits 
AD neuropathology, possibly by insulin’s inhibitory influence on GSK-3 
mechanisms, and therefore might modulate AD neuropathologic expression or 
burden. The results of the voxel-based morphometry experiment in chapter 2, which 
demonstrated greater hippocampal volume in those AD subjects with higher 
peripheral insulin levels, would support the notion that insulin acts reduce pathologic 





The data presented herein describe AD-specific insulin effects on both 
hippocampal volume and function.  The positive correlation between peripheral 
insulin levels and limbic/hippocampal volume in AD would support a neurotrophic 
role for insulin.  The insulin measure used for this exploratory study, insulin AUC 
during a three-hour intravenous glucose tolerance test, represents endogenous insulin 
secretion and production to a standardized glucose challenge, and therefore might be 
less susceptible to day-to-day variation in fasting insulin levels and better reflect 
long-term insulin exposure over a variety of physiologic conditions.  It is important 
to note that the participants in this study were non-diabetic by common definitions.  
Those AD subjects with higher insulin exposure exhibited greater gray matter 
volume in limbic and hippocampal regions.  While it is not clear from these data if 
insulin acts to increase gray matter volume, or rather slows age or disease-related 
atrophy in regions known to express insulin receptors, this relationship adds to the 
growing body of evidence that insulin signaling mechanisms might be important in 
preserving brain health in AD.  An alternate interpretation would suggest that those 
AD subjects exhibiting relative insulin resistance, reflected by higher insulin AUC 
during the three-hour intravenous glucose tolerance test, is beneficial in terms of 
limbic/hippocampal volume.  This scenario seems unlikely however when 
considering the body of evidence indicating that insulin signaling mechanisms are 





The functional MRI results presented herein suggest that insulin might serve 
as neuromodulatory role in AD in addition to the proposed neurotrophic or 
neuroprotective roles.  The memory encoding experiments demonstrate that insulin 
modulates hippocampal activity according to apolipoprotein E-epsilon-4 genotype in 
early AD, with significant decreases in hippocampal activation in apolipoprotein E-
epsilon-4 positive AD.  These changes were paralleled by changes in performance on 
an image recall test, suggesting a link between the imaging and cognitive findings 
and might indicate that insulin has a specific function in hippocampal-based memory 
performance.   
 
Insulin might act to modulate hippocampal activity during memory encoding 
by altering N-methyl-D-aspartic acid (NMDA) receptor function.  Insulin signaling 
mechanisms have been shown to transiently phosphorylate tyrosine residues on 
NR2A and NR2B subunits in rat hippocampal slices, and increasing NMDA activity. 
(Christie, et al., 1999) A similar phenomenon has been observed in xenopus oocytes. 
(Jones & Leonard, 2005)  Insulin appears to restore impaired long-term potentiation 
(LTP) function in rat hippocampal sliced obtained from diabetic rats,  (Izumi, et al., 
2003)  while glucose alone did not restore LTP function, underscoring that insulin 
might have a specific relationship to LTP mechanisms.  Insulin along with low-
frequency stimulation promotes phosphorylation of α-amino-3-hydroxyl-5-methyl-4-




clathrin-mediated endocytosis and long-term depression (LTD) in rat hippocampal 
CA1 neurons. (Ahmadian, et al., 2004)  Insulin-induced changes in these LTP/LTD 
mechanisms might be expected to alter synaptic activity, modulating BOLD 
activation as well as cognitive performance.  How apolipoprotein E-epsilon-4 
genotype however might impact these mechanisms is not clear.  It appears therefore 
that insulin might modulate both LTP and LTD, perhaps in a stimulus-dependent 
manner, at the hippocampus to facilitate cognitive function in AD. 
 
The results of the motor experiment suggest that insulin might affect non-
memory processes according to apolipoprotein E-epsilon-4 genotype in AD, similar 
to the manner noted during the memory task.  While the specific molecular 
mechanisms underlying these observations cannot be determined from these studies, 
the similar response to insulin for both the memory and motor tasks would suggest 
some degree of overlap in the mediators of these effects.  As mentioned earlier, 
insulin administration increases CSF norepinephrine levels and there appear to be 
apolipoprotein E-epsilon-4 based differences in noradrenergic signaling.  It might 
therefore be that insulin’s effects are mediated via noradrenergic signaling 





It is interesting to note that there were no apolipoprotein E-epsilon-4 related 
differences in the relationship between peripheral insulin and limbic/hippocampal 
volume, while there were clearly differences in hippocampal function according to 
this AD risk factor.  Several potential mechanisms by which insulin might act to 
influence neuronal health and function have been described, and this disparity would 
suggest that these two effects are mediated by unique phenomenon. 
 
Brain Insulin Resistance in Alzheimer’s Disease 
 
A recent review summarizes the growing body of evidence suggesting the 
existence of brain insulin resistance in AD.  (de la Monte, 2009)  In brief, there 
appear to be reductions in insulin and insulin-like growth factor (IGF) receptors and 
signaling intermediates that result in impaired glucose utilization similar to that seen 
peripherally in type 2 diabetes mellitus, prompting the term “type 3 diabetes” to 
describe AD pathophysiology.  Impaired insulin signaling also contributes to 
aberrant tau phosphorylation and Abeta deposition, as well as oxidative stress.  Thus, 
the alterations in insulin signaling seen in AD might underlie the anatomic and 






These observations have been described as evidence of brain insulin 
resistance. In a setting of insulin resistance for example, higher insulin levels might 
be able to restore insulin’s beneficial effects on neuronal health and inhibitory 
influence on AD pathology in regions known to exhibit high concentrations of 
insulin receptors, such as the hippocampus.  That we observed a relationship 
between insulin and hippocampal volume in the AD group suggests that chronic 
exposure to higher insulin levels might ameliorate any impairment in insulin 
signaling, and act to preserve hippocampal volume, perhaps by inhibiting AD 
neuropathology. 
 
We further observed insulin-induced changes in hippocampal function in AD 
according to apolipoprotein E-epsilon-4 genotype, suggesting first that this common 
AD risk factor might define two distinct sub-populations with different responses to 
insulin.  In the non-carriers, hippocampal activation showed a non-significant 
increase in hippocampal activation with insulin, while activation in carriers 
decreased with insulin.  This might be interpreted as preliminary evidence of brain 
insulin resistance in terms of acute function in the non-carriers.  Furthermore, 
augmentation of insulin action might be detrimental in apolipoprotein E-epsilon-4 






Interestingly, there does not appear to be apolipoprotein E-epsilon-4 related 
differences in the relationship between insulin and hippocampal volume.  This might 
suggest that the acute and chronic effects of insulin are mediated by unique 
biochemical pathways.  In fact, insulin’s trophic effects involve GSK-3 signaling, 
while insulin’s potential effects on cognition likely involve NMDA and AMPA 
receptors.    
 
The results of the motor control task suggest that insulin might influence non-
memory related tasks as well.  In the overall AD group, brain activation increased in 
several regions, including the ipsilateral somatosensory cortex.  There also appears to 
be an apolipoprotein E-epsilon-4 based difference in motor responses similar to that 
seen during the memory task, suggesting that insulin acts to modulate widespread 
brain physiology.  
 
Changes in general cortical excitability with insulin might explain the 
possible similarities in the insulin responses during the memory encoding and motor 
tasks.  Norepinephrine (NE) is known to modulate cortical excitability and causes the 
inactivation of slow-acting, Ca++ dependent K+ channels in cortical and 




phase of the action potential, and decreasing their current attenuates after-
hyperpolarization, promoting sustained action potential generation. (Andersen, et al., 
2007)   
 
The sole source of brain NE is the locus ceruleus in the pons.  Axons from 
the locus ceruleus project via the medial forebrain bundle to most cortical areas, 
branching several times such that a single locus ceruleus cell body might modulate 
thousands of cortical neurons.  (Aston-Jones & Cohen, 2005) Norepinephrine acts at 
cell body autoreceptors within the locus ceruleus, promoting electronic coupling 
between adjacent locus ceruleus neurons, and coordinated phasic activity.  
Norepinephrine output to cortex from the locus ceruleus is driven by phasic activity, 
and contributes to attentiveness and cognitive performance (Usher, Cohen, Servan-
Schreiber, Rajkowski, & Aston-Jones, 1999)  The effects of norepinephrine on 
phasic activity at the locus ceruleus are regulated by NE reuptake via NE transporter, 
(NET) and the effect of NET modulation on both cortical excitability and cognitive 
performance has been demonstrated with several drugs.  A single dose of reboxetine, 
a selective NE reuptake inhibitor, has been shown to increase cortical excitability as 
measured with transcranial magnetic stimulation, and improve motor skill learning. 
(Plewnia, Hoppe, Cohen, & Gerloff, 2004) Modafinil, a monoamine reuptake 
inhibitor, has been shown to modulate locus ceruleus activity on fMRI, (Minzenberg 




al., 2009; Minzenberg & Carter, 2008; Walsh, Randazzo, Stone, & Schweitzer, 
2004)  Therefore, modulation of locus ceruleus activity by NET inhibition might 
translate to increased cortical excitability and improved memory performance. 
 
Insulin appears to promote phasic locus ceruleus activity by modulating NET 
expression.. Insulin has been shown to inhibit NET mRNA production in rat locus 
ceruleus (Boyd, Clarke, Muther, & Raizada, 1985) in cell culture and after extended 
intraventricular injection. (Boyd, et al., 1985; Figlewicz, et al., 1993)  It might 
therefore be that insulin’s influence on cognitive performance in AD reflects changes 
at the locus ceruleus leading to increase NE output to cortex (including 
hippocampus), resulting in increased cortical excitability, and translating to 
improved cognitive performance.  Changes such as these might partially explain 
some of the finding of this study, however does not address the AD-specific nature 
of those findings, or the apolipoprotein E-epsilon-4 related differences in insulin 
responses.   
 
Degeneration of the locus ceruleus in advanced AD has been well 
documented (Mann, Yates, & Hawkes, 1983; Zweig, et al., 1988) Postmortem 
examination has more recently shown that locus ceruleus degeneration occurs in 




(MCI) and AD. (Grudzien, et al., 2007) The loss of locus ceruleus neurons is 
accompanied by loss of neurons in prefrontal cortex, but the rate of loss in these two 
regions is different, with greater prefrontal neuronal loss compared to that of the 
locus ceruleus.  Furthermore, axons of surviving locus ceruleus neurons undergo 
sprouting, forming additional synapses. (Szot, et al., 2007) This differential rate of 
neuronal loss between the locus ceruleus and cortex, coupled with axonal sprouting 
of locus ceruleus neurons, results in a relative increase in noradrenergic input to 
cortex in AD.  Additionally, AD cortex appears to exhibit increased excitability, 
possibly due to changes in receptor types.  (Di Larzzaro, et al., 2003; Di Larzzaro, et 
al., 2004)  Thus, noradrenergic input from the locus ceruleus to cortex appears to be 
augmented in AD.  If insulin acts to modulate cortical function via noradrenergic 
mechanisms, these pathologic changes might explain in part the observation of 
increased BOLD activation with insulin specifically in the AD group, while the 
control group demonstrated responses with insulin that were the same as with saline.   
 
The apolipoprotein E-epsilon-4 based differences in brain insulin responses 
may reflect differences in noradrenergic signaling mechanisms.  The apolipoprotein 
E-epsilon-4 genotype appears to interact with b2 polymorphisms to confer increased 
AD risk.  These polymorphisms also exhibit different signaling qualities, (Yu, et al., 
2008) suggesting that noradrenergic mechanisms might differ across apolipoprotein 




genotype might be associated with altered noradrenergic signaling in cognitively 
intact older adults.  The antidepressant mirtazapine, which inhibits the reuptake of 
both norepinephrine and serotonin, appears to work faster in apolipoprotein E-
epsilon-4 positive subjects compared to non-carriers.  Interestingly, the selective 
serotonin reuptake inhibitor paroxetine seemed to have the same efficacy across 
apolipoprotein E-epsilon-4 genotype in this same study, (Murphy, Kremer, 
Rodrigues, & Schatzberg, 2003) underscoring the relationship between 
apolipoprotein E-epsilon-4 and NE signaling. While it is not clear how this might 
relate specifically to the results of this study, these studies suggest that 
apolipoprotein E-epsilon-4 based differences in both adrenergic and noradrenergic 
signaling mechanisms might exist.  In the context of the results of this study, the 
existence of such apolipoprotein E-epsilon-4 based differences in noradrenergic 
sensitivity might support the theory that insulin acts to modulate cognitive 
performance and brain responses along apolipoprotein E-epsilon-4 genotype by 
modulating locus ceruleus activity and influencing cortical excitability via a NE-
dependent mechanism. 
 
In summary, insulin appears to exhibit an AD-specific relationship with 
hippocampal volume, which might reflect neurotrophic or neuroprotective effects, 
and adds to the growing body of evidence that brain insulin signaling might be 




memory encoding, but insulin’s effect on hippocampal function appear to differ 
across apolipoprotein E-epsilon-4 genotype, with carriers exhibiting decreased 
activation with insulin.  These changes in hippocampal activation with insulin appear 
to be paralleled by changes in some cognitive measures, suggesting a link between 
imaging and memory findings.  Activation during a motor task also appears to 
increase with insulin in AD, and might follow a similar pattern across apolipoprotein 
E-epsilon-4 genotype.  Insulin however does not appear to influence mean cerebral 
blood flow.   
 
These insulin-related changes might be explained in part by the possibility 
that insulin modulates locus ceruleus activity, and therefore influence cortical 
excitability.  Insulin-induced phasic activity at the locus ceruleus might increase 
norepinephrine output to norepinephrine-hypersensitive AD cortex.  Noradrenergic 
signaling mechanisms might differ according to apolipoprotein E-epsilon-4 
genotype, leading to differential effects both in terms of cognitive and BOLD 






Insulin or insulin-based therapies might offer new hope for Alzheimer’s 
disease patients and their families.  Insulin has been shown to improve cognitive 
performance acutely (S Craft, S Asthana, G Schellenberg, et al., 1999; Craft, et al., 
1996; Murphy, et al., 2003; M. A. Reger, et al., 2007; G. Watson, et al., 2003) and to 
might modulate Abeta metabolism as well (M. A. Reger, et al., 2007; G. Watson, et 
al., 2003) suggesting its use to treat AD clinically.  It seems however that insulin 
itself might not be the best choice for long-term clinical use.   Insulin and Abeta are 
degraded by a common enzyme, insulin-degrading enzyme, and it follows that higher 
insulin levels might actually promote the accumulation of amyloid due to 
competitive inhibition of insulin degrading enzyme.   Since insulin might also 
decrease Abeta production, the net effect on Abeta deposition would probably 
represent a balance between insulin’s potential effect of promoting amyloid 
deposition, and inhibition of Abeta production.  It is not clear where this balance 
however might lie.  Although a single dose of experimentally administered insulin 
appears to be safe, clinical use of insulin therapy for AD might be hazardous since 
cognitively impaired patients might be at increased risk for accidental overdose and 
potentially life-threatening hypoglycemia.  Rosiglitazone, which acts by up-
regulating the transcription of insulin signaling intermediates, is used to increase 
insulin sensitivity in type 2 diabetes, and has been shown to improve cognitive 




et al., 2006)  Such an indirect approach to augmenting insulin’s effects might offer a 
safe alternative to insulin itself, and also circumvents the potential for increased 
Abeta accumulation with insulin. These potential benefits of drugs such as 
rosiglitazone must however be weighed against their cardiovascular risks.  
Furthermore, insulin resistance in type 2 diabetes is modifiable with physical activity 
and lifestyle changes, and these measures might offer some benefit in AD as well.  
Higher levels of physical activity have been shown to be associated with less age-
related cognitive decline and dementia risk, (Verghese, et al., 2003) in support of this 
notion and further suggesting a protective influence of insulin.  Our results also 
suggest that apolipoprotein E-epsilon-4 genotype might be an important 
consideration for future development and application of insulin-based therapies for 
AD.  Thus, measures to improve insulin signaling might have both protective and 
therapeutic benefits for AD, and apolipoprotein E-epsilon-4 genotype might identify 












In all of the presented studies, the diagnosis of Alzheimer’s disease was made 
on clinical grounds, which are by nature imperfect.  The voxel-based morphometric 
analysis presented in chapter 2 is cross-sectional in design, which makes the 
determination of cause and effect relationships impossible.  It is therefore not clear if 
higher insulin levels truly prevent hippocampal volume loss.  The white matter 
results of this study should be interpreted with caution as these might represent 
misclassified periventricular white matter pathology, although the method used 
reduces such error. (Good, et al., 2001)  Lastly, peripheral insulin was used as a 
surrogate measure for CNS insulin, and while CNS insulin is derived from the 
periphery, (Banks, 2004) this may not accurately reflect CNS levels. 
 
The functional MRI studies must be interpreted with some limitation sin 
mind as well.  First, these pilot studies were based on a relatively small sample size, 
which might limit the ability to detect meaningful changes between saline and 
insulin.  Second, several of the demented subjects were taking drugs such as 
cholinesterase inhibitors, NMDA agonists and beta-channel-blockers, which might 
alter fMRI activation patterns.  Third, because of the potential that overt insulin 
resistance could confound the study, we excluded diabetic from participation.  This 




increased diabetes risk.  Forth, we did not measure insulin levels in CSF, and it is 
possible that variable penetration was achieved with the administration method used.  
Fifth, the order of event during each visit was dictated such that the fMRI data would 
be obtained when CSF insulin levels were at their peak after intranasal insulin 
administration as reported in the literature.  Consequently, the cognitive testing 
occurred after the MRI scan, and it appears that any of insulin’s effects might have 
decreased by that time.  The lack of clear cognitive responses to insulin makes it 
difficult to determine if the changes in hippocampal activation observed are 










Degenerative changes within brain noradrenergic systems in AD might be 
contribute to cognitive impairment in AD, and might represent a novel therapeutic 
target.  Drugs that inhibit norepinephrine reuptake such as modafinil and reboxetine 
might have been shown to modulate locus ceruleus activity and improve cognitive 
performance, and therefore deserve study as potential AD treatments.  Their effect 
on hippocampal activation however has not been assessed.  Comparing the effect of 
these drugs, whose mechanism of action is known, to that of insulin might offer 







































Several reports suggest sex-based differences in fMRI activation.  Garn et al 
describe sex-by-category interactions during an object naming task, with selective 
activation of the anterodorsal cingulate and left posterior temporal gyri in females for 
tools, and left posterior middle temporal gyrus for plants in males.  (Garn, Allen, & 
Larsen, 2009)   Interestingly, there appear to be hormonal influences on brain 
function in both men and women.  In addition to several common areas of activation 
during a semantic retrieval task, men exhibited greater left frontal activation than 
women in both the early follicular and midluteal menstrual phases.  In women, left 
frontal activation was shown to correlate with estradiol in the midluteal phase and 
with progesterone during both phases. (Konrad, et al., 2008)  It seems therefore that 
sex might influence the results of fMRI studies, potentially confound imaging 
studies, but these differences might be less significant in older adults.  Few studies 
comparing the influence of sex on brain activation have however focused specifically 
in memory related tasks.  Schmidt et all studies brain activation during an n-back 
memory task in normal adults and found no sex-based differences in either response 
times of brain regions activated during the task.  (Schmidt, et al., 2009)  These 
findings are consistent with an earlier report by Haut et al, showing similar activation 
patterns during working memory and recognition tasks in males and females.   
 
Differences in motor function according to sex have also been described.  




movements in young men compared to young women.(Fukunaga, et al., 2009)  
Women showed greater ipsilateral and contralateral motor cortex activation during a 
finger-tapping task compared to men, while men activated greater subcortical 
activations compared to females.  (Lissek, et al., 2007)  In summary, it seems that 
sex differences during fMRI cognitive tasks might be contextual (i.e. differ 
according to “maleness” or “femaleness” of stimuli such as tools and plants), and are 
likely susceptible to hormonal influences.  Similarly, there appear to be sex-based 
differences in fMRI activation during non-cognitive tasks.   
 
 We therefore assessed sex-based differences in demographic data as well as 
fMRI activation during the memory encoding task described in Chapter 3, and the 
motor task from Chapter 4.  Group differences in age, weight, education, fasting 
glucose and insulin levels, and hippocampal percent activation were assessed with 
the Kruskall-Wallis test.  Differences in plasma glucose and insulin levels between 
the placebo and insulin conditions were assessed with Wilcoxon Signed-Ranks test. 
All statistical analysis outside of imaging space was performed with SPSS 16.0.  A 
random-effects model was used to compare brain responses across sex.  Voxels 
exhibiting differences in activation across sex groups were considered significant at 





 Control Group-Three male and 7 female control subjects participated in this 
study.  The males and females were similar in terms of age, years of education, 
weight, baseline fasting glucose, hippocampal percent activation volume and 
cognitive performance in both the saline and insulin conditions. (Table A-1)  
Analysis of the memory encoding fMRI data showed no sex-wise differences in 
medial temporal lobe or hippocampal activation in the saline condition.  Comparison 
of insulin-related change in fMRI activation during the memory encoding across sex 
however showed greater activation in the males compared to females at the left 
parahippocampal gyrus (x,y,z = -21, -52, 1) (Figure A-1)   Analysis of the motor task 
in the saline condition data showed greater activation in females at the left post-
central gyrus (x, y, x = -39, -40, 58) compared to males.  There were however no 
sex-related differences in insulin related changes in motor activation. 
 
 Early AD Group-Thirteen male and 5 female early AD subjects participated in 
this study.  The males and females were similar in terms of age, years of education, 
baseline fasting glucose, hippocampal percent activation volume and cognitive 
performance in both the saline and insulin conditions.  There was a trend towards 
greater weight in the males compared to the females. (Table A-2)  Analysis of the 
fMRI data revealed greater activation during the memory encoding task in males 
compared to females at the right parahippocampal gyrus (x, y, z, = 9, -1, -23) in the 




compared to females at the left parahippocampal (x, y, z, = -15, -1, -11) and left 
lingual gyri. (x, y, z, = -33, -73, -8)  During the saline condition motor task, females 
showed greater activation than males at the right pre-central (x, y, z = 61, -10, 31) 
and post-central gyri. (x, y, x = 39, -25, 31)  Males however exhibited greater 
insulin-related change in activation than females at the right pre-central gyrus (x, y, z 
= 60, -31, 31 and 33, -13, 58) and post-central gyrus. (x, y, z = 48, -22, 31) 
 
 In summary, cognitively intact males exhibited greater insulin-related increases 
in fMRI signal than females at the left parahippocampal gyrus during the memory 
encoding task.  Similarly, AD males showed greater insulin related increases in 
fMRI signal than females at the left parahippocampal and lingual gyri during the 
memory encoding task.  AD males also exhibited greater insulin related increases in 
fMRI signal than females at the left pre- and post-central gyri during the motor task.    
 
 There were however no significant sex-wise differences in the ROI-based 
assessment of hippocampal activation.  This method takes into account intersubject 
anatomic variation, hippocampal atrophy and image registration errors, and therefore 
might be a more sensitive measure of brain activity.  It is noteworthy that no sex-
wise differences in activation were noted in the whole brain analysis at the 




 The extant literature provides somewhat conflicting information about sex-
related differences in fMRI responses.  Some reports provide convincing evidence of 
differences in pre-menopausal females, but how this might relate to an older, post-
menopausal population is not clear.  Furthermore, some of these differences appear 
to be contextual, and therefore might reflect more complex psychosocial matters 
including gender identity, rather than purely sex differences.  To the extent possible, 
the stimulus used for the memory encoding task was neutral in terms of emotional 
valance and activity content.  The motor task employed was largely devoid of any 
cognitive component.  There should therefore be minimal concern that the contexts 
of theses stimuli underlie the sex-related differences seen.  These differences 
therefore might represent authentic sex-based differences in brain activity, however 
the small sample size, as well as the significantly different sex proportions between 
the groups make it difficult to draw any firm conclusions.  It is possible that some of 
the voxels exhibiting sex-wise differences might be driven by confounding issues.  A 
larger sample size with equal sex proportions might help clarify any sex-related 









Table A-1.  Sex Differences in Control Subjects 
 Males (n=3) Females (n=7) p-value 
Age (years) 72.3 (9.5) 74.1 (5.4) 0.57 
Education (years) 18.3 (2.5) 15.2 (2.3) 0.12 
Weight (lbs) 166.3 (25.8) 142.7 (30.2) 0.21 
Plasma Glucose at Baseline (mg/dl) 96.0 (4.8) 98.8 (15.3) 0.91 
HPAV Saline (%) 21.0 (21.0) 15.6 (14.8) 0.57 
HPAV Insulin (%) 28.1 (14.8) 18.6 (13.6) 0.43 
Global Cognition Saline 0.0 (1.8) -0.1 (0.9) 0.57 












Table A-2.  Sex Differences in Early AD Subjects 
 Males (n=13) Females (n=5) p-value 
Age (years) 73.4 (7.9) 70.4 (7.7) 0.43 
Education (years) 16.1 (4.8) 14.8 (1.9) 0.96 
Weight (lbs) 180.5 (21.7) 149.8 (36.1) 0.07 
Plasma Glucose at Baseline (mg/dl) 93.3 (7.8) 93.3 (13.7) 0.81 
HPAV Saline (%) 14.8 (10.7) 10.6 (6.5) 0.59 
HPAV Insulin (%) 9.4 (7.0) 6.2 (3.2) 0.35 
Global Cognition Saline -0.2 (1.1) 0.4 (1.2) 0.35 
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